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Abstract  V 
Abstract 
Dysferlin is a multi C2 domain protein that belongs to the ferlin family and is localized to 
the T-tubule system in skeletal muscle fibers. It is involved in skeletal muscle 
membrane repair, regeneration and T-tubule biogenesis. The precise biochemical 
function of dysferlin has not been discovered so far, but mutations in the dysferlin gene 
lead to mucular dystrophy. Preliminary data demonstrated that dysferlin induces 
tubulated membranes when heterologeously expressed in non-muscle cells. These 
observations suggested a role of dysferlin in membrane tubulation, and it was the aim 
of this thesis to further examine the biochemical and cell biological of dysferlin  
Analysis of dysferlin-induced tubules in non-muscle cells revealed that these structures 
share biochemical and morphological similarities to T-tubule membranes as they 
incorporate T-tubule phospholipids and invaginate from the plasma membrane. Full-
length dysferlin was required for membrane tubulation, and pathogenic mutations 
impaired membrane deformation capacity. In vitro, dysferlin induces liposome 
tubulation which provides direct morphological evidence for a powerful membrane 
tubulation capacity.  
In this thesis it was further demonstrated that the alteration in T-tubule morphology of 
dysferlin-deficient muscle lead to increased Ca2+ release probably through excitation-
coupled Ca2+ entry. This effect was not due to a secondary alteration of triad- or T-
tubule associated proteins and resulted in increased exercise capacity in juvenile 
dysferlin-deficient mice similar to the phenotype of presymptomatic patients affected by 
dysfelin-deficient muscular dystrophy. 
Also in heart muscle dysferlin was required for a morphologically and functionally intact 
T-tubule system. Functional alterations in Ca2+ homeostasis were compensated under 
normal physiological conditions but induced severe arrhythmogenic events in stress 
situations. 
Taken together, we provide direct evidence that dysferlin induces membrane tubulation 
defining a novel function of this protein. The abnormal T-tubule system affects Ca2+ 
homeostasis in skeletal and heart muscle. These findings may have important clinical 
implications, and modulation of Ca2+ homesostasis in dysferlin-deficient muscular 
dystrophy should be investigated as a possible translational therapeutic approach.  
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Introduction  1 
1. Introduction 
1.1 The muscular dystrophies 
Muscular dystrophies are a heterogenous group of inherited disorders of skeletal 
muscle which can manifest in any age from childhood to adolescence. These diseases 
are characterized by progressive muscular weakness and wasting due to degeneration 
and loss of muscle fibers. Most muscular dystrophies lead to a massive increase of 
serum creatine kinase and muscle pathology with de- and regenerating fibers with 
centralized nuclei, inflammation, increase in fiber size variation and replacement of 
intact muscle fibers by fat and fibrous tissue. Several genes could be identified in the 
last decades that are responsible for these diseases, but most of the underlying 
pathomechanisms leading to muscle degeneration are still unknown and therefore no 
curative treatment is available. A major step towards the identification of the molecular 
mechanisms behind these disorders was the discovery of dystrophin (Koenig et al., 
1988) and its association with the dystrophin-glycoprotein complex (DGC). Mutations in 
the dystrohin gene lead to the most common muscular dystrophy, Duchenne muscular 
dystrophy. The DGC is a multisubunit complex which links the subsarcolemmal actin 
cytoskeleton with the extracellular matrix thereby stabilizing the plasma membrane 
(Laval and Bushby, 2004). Loss of dystrophin or other proteins associated with the 
DCG lead to plasma membrane destabilization. Muscle fibers are permanently 
exposed to mechanical stress due to shearing forces that work on the plasma 
membrane of the muscle fibers during the process of contraction and relaxation. 
Therefore, muscle fibers with destabilized DGC due to mutations of DGC genes are 
prone to membrane ruptures which then lead to degeneration of the muscle fiber 
(Staub and Campbell, 1997). This emphasizes the crucial role of an intact plasma 
membrane in skeletal muscle physiology.  
1.2 Dysferlin-deficient muscular dystrophy 
Mutations in the dysferlin gene were found to be the cause of three clinical diseases, 
autosomal recessive limb-girdle muscular dystrophy type 2B (LGMD2B; OMIM# 
253601, Bashir et al., 1998), Miyoshi Myopathy (MM; OMIM# 254130, Liu et al., 1998) 
and distal anterior compartment myopathy (OMIM #606768, Illa et al., 2001). As the 
number of patients affected with dysferlinopathies is estimated between 1/100,000 and 
1/200,000 (Moore et. al., 2006) it is a rare muscular dystrophy. Patients present with 
muscle pain and muscle weakness in either proximal (LGMD2B) or distal (MM) 
muscles. During the course of the disease with typically slow progression the 
phenotypes overlap and muscle degeneration spreads from distal to proximal muscles 
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and vice versa so that all limb-girdle muscles are affected. Age of disease onset is very 
heterogeneous but most patients show first symptoms in the second decade of life. 
Bansal et al. showed that dysferlin is distinct from the DGC as dysferlin-null mice 
developed a slowly progressive muscular dystrophy but maintained a functional 
dystrophin-glycoprotein complex. Furthermore they showed that absence of dysferlin 
leads to defects in the plasma membrane repair system (Bansal et al., 2003). 
Therefore it was concluded that defective membrane repair but not instability and 
defects of the plasma membrane structure lead to loss of muscle fibres in 
dysferlinopathy. This was a first hint towards a different pathomechanism as compared 
to DGC deficiencies. The role of dysferlin in membrane repair was substantiated by the 
fact, that patient muscles show accumulation of vesicles in sub-sarcolemmal regions 
(Piccolo et al., 2000, Cenacchi et al., 2005). Furthermore, dysferlin-deficient muscle 
fibres show defective muscle differentiation due to delayed expression of myogenin (De 
Luna et al., 2006). In contrast to patients with other forms of musclular dystrophy 
dysferlinopathy patients show increased levels of fitness before onset of symptoms 
(Klinge et al., 2009). So far this observation is not understood but it leads to the 
hypothesis that the molecular pathomechanism underlying the disease is not 
sufficiently resolved. Muscle tissue is permanently exposed to mechanical stress and 
therefore plasma membrane ruptures. As patients are initially without symptoms and 
have a high level of fitness, it seems unlikely that the disease is based on a defective 
membrane repair system alone. McNeil and Steinhardt claimed that membrane repair 
is a prerequisite for evolutional development of force generating tissue which further 
hints towards other molecular pathomechanisms underlying the disease.  
1.2.1 The dysferlin gene an its orthologues 
The dysferlin gene is located on chromosome 2p13. The most common transcript 
encoded by the dysferlin gene includes 55 exons and alternative splicing leads to 
several isoforms (Aoki et al., 2001). Among them, isoform 8 is commonly used to 
describe the dysferlin gene. With 90 % sequence similarity between mouse and human 
dysferlin is well conserved among the mammals (Vafiadaki et. al., 2001).  
Mutations of the dysferlin gene are scattered throughout the whole coding sequence 
without any apparent hotspot. Mainly point mutations and small insertions or deletions 
are found but larger exonic deletions or duplications do also exist. Many dysferlin 
mutations lead to degradation through the nonsense-mediated mRNA decay process 
(Wenzel et al., 2006) and others lead to truncated or unstable versions of the protein 
that are degradated by autophagy or the endoplasmatic reticulum (ER) associated 
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degradation system (Fujita et al., 2007). Furthermore, no genotype-phenotype 
correlation was found (Krahn et al., 2009, Klinge et al., 2008, Klinge et al. 2009).  
The dysferlin protein translated from isoform 8 is a 230 kDa protein which belongs to 
the ferlin family. The ferlins are named after their homology to Fer1 which was 
originally identified in C. elegans. Fer1 mediates Ca2+-dependent fusion of 
membranous organelles to the plasma membrane in developing spermatids (Achanzar 
and Ward, 1997, Washington and Ward, 2006). Human orthologues of dysferlin are 
otoferlin, myoferlin and FER1L5. Otoferlin is located in the inner ear at the inner hair-
cell and is known to play a role in exocytosis of synaptic vesicles and is needed for 
Ca2+- dependent vesicle-plasma membrane fusion (Roux et al., 2006). Myoferlin is 
most related to dysferlin and is highly expressed in fusing myoblasts. It is known to be 
involved in myoblast-myoblast and myoblast-myotube fusion which are critical events 
during muscle development and repair (Davis et al., 2000, Doherty et al., 2005). 
Additionally, myoferlin and also FER1L5 were demonstrated to interact with vesicle 
recycling proteins EDH1 and EDH2 (Doherty et al., 2008, Posey et al., 2011). Loss of 
function mutation of otoferlin leads to nonsyndromic deafness (Yasunaga et al., 1999) 
but so far no human pathologies have been described for myoferlin and FER1L5. In 
human and mouse genomes two further genes are present, FER1L4 and FER1L6, but 
not much is known about their function or protein expression. 
1.2.2 The dysferlin protein and its C2 domains 
All proteins of the ferlin family have a very similar protein structure (see figure 1.2.2). 
They all are type II transmembrane proteins and have a carboxy-terminal 
transmembrane domain. Furthermore, they all contain multiple copies of C2 domains 
which are known to play a role in phospholipid interaction (Davis et al., 2002). C2 
domains were first described in proteinkinase C where they are involved in Ca2+-
dependent membrane binding. Most of the C2 domain proteins have maximal three C2 
domains. Besides the ferlins only two gene families have been described with three or 
more C2 domains; the multiple C2 domain and transmembrane region proteins (Shin et 
al., 2005) and the extended synaptotagmins (Min et al., 2007) but the precise function 
of multiple C2 domain proteins remains so far unknown. Dysferlin contains seven C2 
domains that show high similarity to the synaptotagmin VII C2 domains which are 
involved in Ca2+-triggered fusion of synaptic vesicles with the plasma membrane in 
neurons (Sutton et al., 1995). The classical function of C2 domains is Ca2+-dependent 
lipid binding but some C2 domains are involved in membrane trafficking and signal 
transduction by mediating protein-protein interaction without Ca2+-binding abilities 
(Nalefski and Falke, 1996). C2 domains form an eight-stranded antiparallel ß-sandwich 
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consisting of two four-stranded ß-sheets which are connected by highly variable 
surface loops in terms of amino acid composition and conformation (Rizo and Südhof, 
1998). Two different topologies of C2 domains were shown which seem to be important 
for protein function (Nalefski and Falke, 1996). Dysferlin C2A, C2B and C2E domains 
have topology I like the C2A domain of synaptotagmin I and the other four C2 domains 
belong to the type II topology domains like the C2 domain of proteinkinase Cδ 
(Therrien et al., 2006). The Ca2+ binding site is built of three Ca2+ binding loops which 
reside on one end of the sandwich and contain negatively charged residues that are 
responsible for Ca2+ binding thereby influencing the electrostatic potential of the 
membrane as a prerequisite for phospholipid binding (Shao et al., 1997). Additionally, 
the residue composition of the loop provides the specificity for the targeted membranes 
as it influences the phospholipid selectivity (Cho et al., 2006). Despite the fact that to 
date the purpose of multiple C2 domains is unknown it should be mentioned that 
sequence analysis of the ferlin C2 domains reveals a great diversity. Each domain 
seems to be more similar to its counterpart in paralogs than to the other C2 domains of 
the same ferlin (Washington and Ward, 2006, see figure 1.2.2) leading to the 
hypothesis, that all C2 domains of dysferlin are different and are therefore needed for 
proper protein function.  
 
 
Figure 1.2.2: Domain structure of ferlins and phylogenetic tree of C2 domains A) Domain 
structure of Fer1 and mammalian ferlin-like proteins. B) Phylogenetic tree based on alignment 
of ferlin C2 domains (from Han and Campbell, 2007). 
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So far phospholipid binding ability was shown for the C2A domain of dysferlin. This 
domain binds negatively charged phospholipids in a Ca2+-dependent manner which is 
abolished by mutations in this domain (Davis et. al., 2002). Furthermore, the C2A 
domain was shown to bind phosphatidylinositol 4-phosphate (PI4P) and 
phosphatidylinositol (4,5)-bisphosphate (PIP2) in presence of Ca2+ (Therrien et al., 
2009). Much less is known about the other C2 domains of dysferlin. Like C2A they 
seem to bind phosphatidylserine, but the binding affinity seems to be much weaker and 
independent of Ca2+ (Therrien et al., 2009). Only recently it was published that the C2 
domains of dysferlin as well as oto- and myoferlin are able to alter the packaging of 
membrane vesicles indicating a membrane sculpting function of the dysferlin C2 
domains (Marty et al., 2013).  
The dysferlin gene contains two further motifs, the DysF sequences which are 
conserved between orthologues and the ferlin domains. For both of the motifs no 
function could be established so far. Ferlin domains are present in all ferlin family 
proteins, but the DysF domain can be found as an unusual nested repeat in only three 
of the ferlins. Further it is present in yeast peroxisomal proteins where it is important for 
regulation of peroxisome size and number (Yan et al., 2008). The structure of the 
myoferlin DysF domain has already been solved and showed two long antiparallel ß-
strands (Patel et al., 2008). Proper folding of the DysF domain seems to be important 
for proper protein function, as many disease-causing mutations can be found in this 
region. Additionally, PEST sequences, which are known to play a role in protein-protein 
interaction and protein degradation by the proteasome (Rechsteiner and Rogers, 1996) 
and nuclear localization signals are present in the dysferlin gene. The dysferlin protein 
typically does not localize to the nucleus, but these sequences may be relevant for 
truncated versions of the protein. 
1.2.3 Binding partners of dysferlin 
To date, several binding partners of dysferlin could be identified. The first interaction 
partner of dysferlin that has been discovered is caveolin 3 (Matsuda et al., 2001). The 
protein is the crucial structural component of caveolae localized at the plasma 
membrane and at the intersection between T-tubule network and the sarcolemma in 
skeletal and heart muscle and is involved in T-tubule biogenesis (Murphy et al., 2009, 
Parton et al., 1997). Mutations in the caveolin 3 gene lead to LGMD1C and rippling 
muscle disease. Caveolin 3-deficient patients show reduced sarcolemmal localization 
of dysferlin, therefore a role of caveolin 3 in recruiting dysferlin to plasma membrane 
and to the T-tubules was proposed (Hernandez-Deviez et al., 2006). Affixin, a focal 
adhesion molecule and annexin I and II, Ca2+ and phospholipid binding proteins, were 
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also shown to interact with dysferlin in skeletal muscle (Lennon et al., 2003, Matsuda et 
al., 2005) but are not directly involved in any human disease. It was proposed, that 
Ca2+-dependent interaction of dysferlin with the annexins is needed for aggregation and 
fusion events after membrane injury (Lennon et al., 2003). Two proteins involved in 
cytoskeleton regulation are known to interact with dysferlin; calpain 3 and AHNAK 
(Anderson et al. 2000, Huang et al. 2008, Huang et al. 2007). Calpain 3 is skeletal 
muscle specific Ca2+-dependent cysteine protease whose substrates are mainly 
cytoskeleton components. The role of calpain 3 is therefore thought to be regulation of 
cytoskeleton structure and interaction of cytoskeleton and plasma membrane. 
Furthermore, calpain 3 is a triad-associated protein and interacts with ryanodine 
receptor (RyR). Absence of the protein leads to decreased Ca2+ release from the SR 
which probably explains muscle weakness in calpain 3-deficient patients (Kramerova et 
al., 2008). Mutations of calpain 3 lead to LGMD2A and underlying pathomechanisms 
involve deregulation of sarcomere structure due to lack of calpain 3-mediated 
proteolysis (Duguez et al., 2006). As AHNAK is not present in T-tubule membranes, it 
colocalizes with dysferlin at the sarcolemma (Huang et al., 2007). The large protein 
localizes at large-scale vesicles called enlargeosome which are involved in cell 
membrane differentiation and repair and signal transduction through interaction with 
other proteins (Haase et al., 1999, Borgonovo et al., 2002) but the exact function of this 
protein is unknown so far and the protein is not directly involved in any human disease. 
In vitro interaction of dysferlin and mitsugumin 53 was reported but so far no in vivo 
evidence is available (Cai et al., 2009). It was proposed that mitsugumin 53 recruits 
dysferlin to the side of injury as mitsugumin 53 acts as sensor for extracellular oxidative 
molecules which enter the cell on the side of injury and mitsugumin 53 containing 
vesicles are transported to these sites (Cai et al., 2009).  
1.3 Therapeutic approaches 
Several studies addressing therapy of dysferlinopathies have been published but until 
now no curative therapy could be established. Studies testing different pharmacological 
substances have been conducted, but none of these could improve muscle pathology. 
Dysferlin-deficient patients show an increased immune response including infiltration 
and increased phagocytic activity of monocytes in their muscles (Gallardo et al., 2001, 
Nagaraju et al., 2008) and it was proposed that the aggressive immune response may 
play a role in disease progression. Therefore studies using a Rho-kinase inhibitor were 
performed as it limits the inflammatory response due to inhibition of the rho-pathway 
which plays a crucial role in many immune cell activities. Nevertheless, the decreased 
immune response did not lead to increased muscle strength or inhibition of 
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degeneration (Rayavarapu et al., 2010). In contrast to that, inhibition of B cells by 
rituximab© leads to a slight increase in muscle force indicating a possible role of B cells 
in muscle pathology (Lerario et al., 2010). Dantrolene is known to inhibit excitation 
contraction coupling by binding to the (RyR) and inhibiting Ca2+ release from the 
sarcoplasmatic reticulum (SR) (Krause et al., 2004). The exact mechanism is still 
unknown but interestingly, dantrolene was able to increase the disease course in two 
dysferlin-deficient patients (Hattori et al., 2007). In addition to these immunological 
approaches, gene therapy could be a possible way to overcome muscle pathology in 
dysferlin-deficiency. Neverthesless, gene therapy by transfer of the dysferlin gene is 
not a trivial method as dysferlin is a large protein of about 230 kDa and encapsulation 
size of adeno-assosiated viruses is normally restricted to 4 kb. Therefore two 
independent viruses had to be used to express dysferlin. One vector carried the 5’ part 
of the cDNA and a donor splice site in an intronic sequence, the other vector carried 
the 3’ part of the sequence and an intronic sequence containing a donor splice site. 
Injection of both vectors in muscle of dysferlin-deficient mice leads to expression of full-
length dysferlin due to formation of intermolecular circular concatamers between the 
two independent vector genomes (Lostal et al., 2010). Using this method it was 
possible to improve membrane repair and locomotor activity in treated mice. Another 
possibility to overcome size limitations in gene transfer is transfer of minigenes. Krahn 
et al. identified a minidysferlin gene in a patient with late onset and moderate 
dysferlinopathy which was used for injection into dysferlin deficient mouse muscles via 
AAV mediated gene transfer (Krahn et al., 2010). The minidysferlin protein was 
correctly localized to the sarcolemma and the T-tubule system and was demonstrated 
to efficiently repair membrane lesions. Nevertheless, the minidysferlin seems not to be 
completely functional, as no histological improvement of treated muscles was 
observed. This further indicates that the disease is not based on a defective membrane 
repair alone. 
1.4 Mouse models of dysferlinopathy 
Several dysferlin-deficient mouse models are available to study the disease. First of all, 
two naturally occurring mice strains have been observed, which reveal dystrophic 
phenotypes. The SJL/J mouse carries a splicing mutation of the dysferlin gene making 
it a model for MM and LGMD2B (Bittner et al., 1999, Vafiadaki et al., 2001). One 
disadvantage of this mouse strain is the fact that the mouse is very susceptible to 
autoimmune diseases like inflammatory muscle disease and experimental autoimmune 
encephalomyelitis, lymphoma and virus infections and influences on skeletal muscle 
can not be excluded. The A/J mouse presents with a mild progressive muscular 
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dystrophy and was shown to contain a retrotransposon insertion in the dysferlin gene 
(Ho et al, 2004). A matched control strain is not available for both of these mouse 
strains, therefore genetically engineered dysferlin knock-out mice strains have been 
established (C57BL/10.SJL-Dysf, B6.129-Dysftm1Kcam, B6.A/J-Dysfprmd) which 
probably are better models for dsyferlinopathy (Bittner et al., 1999, Bansal et al., 2003, 
Ho et al., 2004). B6.129-Dysftm1Kcam mice which were used in this thesis develop a 
slowly progressive muscular dystrophy that starts with the age of two month with 
appearance of single necrotic fibers. All typical features of dystrohphic muscle are 
present at the age of 8 month (Bansal et al., 2003). 
1.5 Dysferlin and its role in T-tubule biogenesis 
The dysferlin protein is expressed mainly in heart and skeletal muscle but can also be 
found in monocytes and macrophages, brain or lung tissue or in the placenta (Bashir et 
al., 1998, Liu et al., 1998, Ho et al, 2002, Vandre et al., 2007). In skeletal muscle, 
dysferlin expression can be detected from 5 to 6 weeks of human embryonic 
development, the time, when limbs start to show regional differentiation (Anderson et 
al., 1999) and the dysferlin protein was localized to the plasma membrane and the T-
tubule system (Anderson et. al., 1999, Ampong et al., 2005, Klinge et al., 2008). It was 
demonstrated that dysferlin associates to the T-tubule system in differentiating 
myotubes in vitro and in vivo and translocates to the sarcolemma after muscle fiber 
injury (Klinge et al., 2007). This lead to the suggestion, that dysferlin is involved in T-
tubule biogenesis. Furthermore, during regeneration dysferlin was localized to the T-
tubule system and only in later stages of regeneration it translocated to the 
sarcolemma. The proposed role of dysferlin in T-tubule development was further 
substantiated by the fact, that dysferlin-deficient mice are characterized by a highly 
abnormal configuration of the T-tubule system with dilated and longitudinally oriented 
tubules (Klinge et al., 2010). Additionally, the dysferlin C2A domain was demonstrated 
to bind to PIP2, a highly negatively charged phospholipid that is present in T-tubule 
membranes (Milting et al., 1994). The T-tubule system is an extensive membranous 
system of skeletal and heart muscle which is necessary for propagating the action 
potential into the interior of the muscle fiber thereby initiating the process of excitation 
contraction coupling (EC-coupling) which results in Ca2+ release from the SR and 
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following contraction of the muscle fiber. Further, the T-tubule system is involved in 
intracellular membrane transport and provides a membrane reservoir for the plasma 
membrane in muscle fiber regeneration (Engel and Franzini-Armstrong, 2004).  
1.6 Biogenesis of the T-tubule system 
Biogenesis of the T-Tubule system is a complex mechanism which is not completely 
understood so far. One model of T-tubule development suggests that tubules derive 
from the plasma membrane trough a mechanism similar to endocytosis (Ishikawa, 
1968). Another model suggests development of tubules through addition of new 
membranes by a mechanism similar to exocytosis (Schiaffino et al., 1977). The real 
mechanism of T-tubule development may also involve features of both models, so that 
plasma membrane vesicles are endocytosed and subsequently fused to T-tubules 
invaginated from the plasma membrane. In developing mouse muscle T-tubules are 
first identified after fusion of myoblasts to multinucleated myotubes at E15. They 
invaginate from the sarcolemma and extend within the myofiber appearing as 
longitudinal orientated membranes. Later they develop short transverse segments but 
until birth stay predominantly longitudinal (Veratti, 1961, Kelly, 1980). Two weeks after 
birth a rearrangement of tubules takes place and tubules appear now mainly in a 
transverse orientation. Final maturation of tubules is completed in mouse 3 weeks after 
birth (Takekura et al., 2001a, Franzini-Armstrong, 1991). T-tubule membranes form 
anatomical triad junctions with the longitudinally oriented sarcoplasmatic reticulum 
which are already established before birth (see figure 1.6). Therefore, the mature 




Figure 1.6: T-tubule system and triad organization in skeletal muscle. a) Electron 
micrograph of a triad junction. A central T-tubule is flanked on both sides by a terminal cisternae 
element from the SR. Arrows indicate electron-dense junctional feet corresponding to the RyR-
DHPR complex. b) Schematic representation of a skeletal muscle sarcomere and surrounding 
membranes (from Al-Qusairi and Laporte, 2011).    
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1.6.1 Other proteins involved in T-tubule biogenesis 
Besides dysferlin, two further proteins have been implicated in T-tubule biogenesis; 
Bin1, also known as amphiphysin II and caveolin 3. Caveolin 3 associates to the 
developing T-tubule system; therefore caveolae and caveolin 3 have been postulated 
to play a role in T-Tubule biogenesis (Parton et al., 1997). This was substantiated by 
the fact, that caveolin 3 knock-out mice reveal T-tubule abnormalities with dilated and 
longitudinal oriented tubules (Galbiati et al., 2001, Minetti et al., 2002). Later it was 
demonstrated that caveolin 3 also localized to the T-tubule system in mature muscle 
fibers where it is clustered in so called hot spots at the opening of the T-tubules 
immediately beneath the sarcolemma (Murphy et al., 2009). The altered structure of 
the T-tubule system after loss of caveolin 3 leads to alteration of the Ca2+ homeostasis 
as it was shown that L-type Ca2+ channel function is reduced in caveolin 3 deficient 
mice (Couchoux et al., 2007). The fact that the T-tubule system in caveolin 3 null mice 
shows abnormalities, but is still present and at least has no overt influence on mortality, 
further proteins seem to be involved in T-tubule biogenesis. One of these is the bar 
domain protein Bin1 which is known to induce membrane invaginations (Frost et al., 
2008), and as it is distributed on the T-tubule system it seemed to be involved in 
tubulogenesis (Lee et al., 2002). By Lee et al. it was shown that the N-terminal BAR 
domain of Bin1 is able to induce deformation of membrane bilayers through its 
interaction with cell membrane phospholipids (Lee. et al., 2002). It was demonstrated in 
CHO cells that Bin1 is able to induce membrane tubules which was abolished by 
mutation of the Bin1 BAR domain. Furthermore, a disrupted T-tubule system was 
detected in Drosophila melanogaster after Bin1 knockout (Razzaq et el., 2001), in adult 
skeletal muscle fibers after Bin1 knockdown (Tjondrokoesoemo et al., 2011) and in 
muscle biopsies of Bin1-deficient patients (Toussaint et al., 2011). This implicates a 
role of Bin1 not only in T-tubule development but also in maintenance of intact 
membrane structure. The disrupted T-tubule system in Bin1 knockdown muscle fibers 
leads to disruption of L-type Ca2+ channel, also known as dihydropyridine receptor 
(DHPR) and RyR coupling which influences Ca2+ homeostasis. Reduced Ca2+ release 
and breaks in Ca2+ transient amplitudes were detected in Bin1-deficient muscle fibers 
(Tjondrokoesoemo et al., 2011). Mutations of Bin1 lead to centronuclear myopathy 
which was claimed to be due to the defective T-tubule remodeling (Nicot et al., 2007). 
A disrupted T-tubule system was also detected in mitsugumin 29- (Nishi et. al., 1999), 
myotubularin 1- (Al-Qusairi et al., 2009) and junctophilin 1-deficient muscles (Ito et al., 
2001, Komazaki et al., 2002). These proteins have not been implicated in biogenesis of 
the T-tubule system but seem to be important for maintenance or formation of the triad 
structure.
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1.7 The triad and the process of EC-coupling 
The triad is an anatomical structure where T-tubule system and the terminal cisternae 
of the SR interface (see figure 1.6). Here, a close contact is established between the 
voltage sensitive DHPR at the T-tubule membrane and the RYR, a Ca2+ release 
channel at the SR membrane which allows coupling of the neuronal signal along the T-
tubules and the Ca2+ release from the SR with following muscle contraction. 
Interestingly in DHPR and in RyR KO mice a normal triad structure was detectable 
(Takekura et al., 1995, Flucher et al., 1993). This suggests that both proteins are not 
needed for proper triad formation but other proteins have to be required for normal 
formation of the triad. The triad proteins junctophilin 1, which provides a structural basis 
for triad formation as it bridges the SR to the T-tubular membrane (Takeshima et al., 
2000), mitsugumin 29 and myotubularin 1 have already been implicated in the process 
of triad structure formation or maintenance. Interestingly, most of the proteins 
mentioned above, which are proposed to be involved in triad formation or T-tubule 
biogenesis have been shown to influence the process of EC-coupling and therefore 




Figure 1.7: Proposed models for store-operated Ca
2+
 entry (SOCE) and excitation-
coupled Ca
2+
 entry (ECCE) a) The Ca
2+
 sensor STIM1 at the SR membrane is required for 
opening of Ca
2+
-permeable ORAI1 channels in the T-tubule membrane. b) ECCE requires 
interaction of DHPR and RyR but the exact channel for Ca
2+
 entry remains to be identified (from 
Lyfenko and Dirksen, 2008). 
 
The process of EC-coupling in skeletal muscle starts with propagation of the action 
potential along the T-tubular membrane into the interior of the muscle fiber where it 
opens the DHPR. This leads to influx of Ca2+ into the cytoplasm and to conformational 
change of the DHPR and thereby activation of the RyR1 which results in rapid Ca2+ 
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release from the SR and initiation of muscle contraction (reviewed in Dulhunty, 2006). 
The rise in global intracellular Ca2+ leads to binding of Ca2+ to troponin C and 
activationof contraction. Ca2+ is then transported back into the SR by the 
sarcoplasmatic reticulum Ca2+ ATPase (SERCA) and outside of the cell by plasma 
membrane Ca2+ ATPase (PMCA) and sarcolemmal Na2+/Ca2+ exchanger (NCX) 
thereby terminating the process of contraction. Inside the SR the free Ca2+ 
concentration is kept low by Ca2+ binding proteins like the main skeletal muscle Ca2+ 
buffer calsequestrin. This is necessary to provide a pool of Ca2+ that is available to 
maintain free Ca2+ levels and to minimize Ca2+ leakage through the RyR and energy 
waste of SERCA. Additionally, calsequestrin modulates RyR1 Ca2+ release from the 
SR (Royer and Rios, 2009). The coupling of DHPR and RyR is bidirectional, meaning 
DHPR controls RyR-mediated Ca2+ release in orthograde direction and in turn RyR 
mediates Ca2+ flux through DHPR in retrograde mode (Nakai et al. 1996). Two further 
Ca2+ entry mechanisms have been demonstrated so far. Store-operated Ca2+ entry 
(SOCE) was detected, when Ca2+ was re-added to the extracellular medium of muscle 
fibers with previously depleted SR Ca2+ store and fibers started to refill their SR stores 
(Kurebayashi and Ogawa, 2001, figure 1.7). Several proteins are proposed to be 
involved in this process but the exact mechanism remains to be identified. Most studies 
favor a model of SOCE involving interaction of stromal interaction molecule 1 (STIM1) 
with Ca2+ release-activated Ca2+ channel protein 1 (ORAI1). STIM1 is localized at the 
SR and has Ca2+ sensing properties. In response of SR Ca2+ content decrease, Ca2+ 
dissociates from STIM1 which leads to conformational changes and clustering of 
STIM1 molecules at the SR membrane. ORAI1 channels which are localized at the T-
tubule membrane in close vicinity to the SR membrane become activated upon STIM 1 
oligomerization and mediate Ca2+ entry into the cell (Dirksen, 2009). Therefore, efficient 
SOCE can only be provided through close contacts of SR and T-tubule membranes at 
the triad junction which is primarily mediated by junctophilin 1. Further models that 
require interaction of RyR or inositol-3-phosphate receptor with transient receptor 
potential canonical type 3 have been proposed but seem not to play a major role in 
SOCE. Later, a store-independent mechanism of Ca2+ entry was identified which was 
dependent on prolonged or repetitive depolarization and was termed excitation-coupled 
Ca2+ entry (ECCE; Cherednichenko et al., 2004, figure 1.7). This mechanism requires 
interaction of DHPR and RyR but the channel responsible for Ca2+ entry is still under 
debate. Bannister et. al. claimed that the DHPR itself is the main and perhaps only 
contributor for Ca2+ entry during ECCE (Bannister et al., 2009). 
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1.7.1 Influence of abnormal T-tubule morphology on EC-coupling 
As mentioned above, several proteins were identified that are involved in T-tubule 
biogenesis or maintenance of triad structure and their absence leads to disorganized T-
tubule morphology. Due to the altered morphology of the T-tubule system most of 
these proteins have influences on Ca2+ homeostasis of the skeletal muscle fibers. Bin1 
knockdown in murine flexor digitorum brevis (FDB) muscles leads to reduced Ca2+ 
transient amplitudes and reduced SR Ca2+ content probably due to compromised 
coupling of DHPR and RYR. Furthermore induction of Ca2+ sparks after osmotic shock 
was decreased because of compromised DHPR activation (Tjondrokoesoemo et al., 
2011). Similar to Bin1 also myotubularin-deficient muscle fibers show defective RyR1-
mediated Ca2+ release from the SR combined with a decrease of RyR1 protein level 
(Al-Qusairi et al., 2009) and loss of caveolin 3 reduces the amplitude of DHPR Ca2+ 
current (Couchoux et al., 2007). On the other hand, an abnormal triad structure has 
been shown to influence the process of SOCE as mitsugumin 29-deficiency leads to 
dysfunction of SOCE making the muscle fibers highly susceptible to fatigue (Pan et al., 
2002) and junctophilin 1-deficiency also leads to reduced SOCE (Li et al., 2010). These 
results indicate that abnormal T-tubule biogenesis and therefore abnormal T-tubule 
structure or an abnormal formation of the triad structure have direct influences on Ca2+ 
homeostasis. 
1.8 Dysferlin and cardiomyopathy 
As mentioned above, besides its expression in skeletal muscle dysferlin is highly 
expressed in heart muscle. Patients with dysferlin-deficient muscular dystrophy present 
primarily with defects of the skeletal muscle, but cardiomyopathies have also been 
described (Guglieri et al., 2008; Wenzel et al., 2007). In mouse models of dysferlin-
deficiency it was found that stress induced by isoprenaline treatment leads to 
development of cardiomyopathy (Wenzel et al., 2007). Furthermore, dysferlin deficient 
mice develop mild dilative cardiomyopathies when getting old which are further 
impaired by stress exercise (Han et al., 2007). A role of dysferlin in heart function has 
not been extensively examined so far but observations from patients and animal 
models suggest a role of dysferlin in heart function. 
1.8.1 EC-coupling in cardiomyocytes 
The mechanism of EC-coupling in cardiomyocytes is similar to the one in skeletal 
muscle. One major difference is the coupling of DHPR and RyR2 which is not 
mechanical but mediated by Ca2+. Upon myocyte membrane depolarization, Ca2+ 
enters the cell through the DHPR and this leads to and is absolutely required for 
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opening of RyR2. Ca2+ is therefore released from the SR by Ca2+-induced Ca2+ release 
(Bers, 2002). After initiation of contraction, Ca2+ is pumped back into the SR by 
SERCA2a and out of the myocyte by PMCA and NXC which is also able to act in 
reverse mode which then contributes to Ca2+ influx in systole (Bers, 2002). The exact 
amount of Ca2+ released into the cytosol by DHPR and NCX has to be exported again 
out of the cell mainly by NCX and to a lesser extent by PMCA. The amount of Ca2+ 
released from the SR hast to be transported back by SERCA2a. A further difference 
between cardiac and skeletal EC-coupling is the mechanism of SOCE which probably 
plays only a minor role in healthy cardiomyocytes. Many studies have reported STIM 1 
and the mechanism of SOCE to be present in neonatal cardiomyocytes and further, 
SOCE was demonstrated to play a role in cardiac hypertrophy (Luo et al., 2012), but its 
contribution to normal Ca2+ homeostasis and its relationship to the mechanism of EC-
coupling remains poorly understood. In present accepted models of Ca2+ homeostasis 




Figure 1.8.1: Excitation-contraction coupling in cardiomyocytes. Due to the action potential 
voltage gated DHPR channels open and Ca
2+
 entry leads to opening of RyR. This is followed by 
Ca
2+
 release into the cytoplasm where contraction is initiated. Ca
2+
 is transported back by 
SERCA, NCX and PMCA. Inset shows time course of action potential, Ca
2+
 release and 
contraction (from Bers et al., 2002).  
 
At the triad junction, about 25 DHPR molecules are coupled to about 100 RyR proteins 
forming a so called Ca2+ release unit (Bers and Guo, 2005). Spontaneous Ca2+ release 
from a single release unit is called a Ca2+ spark. These Ca2+ sparks appear during rest 
as well as during EC-coupling. During EC-coupling thousands of Ca2+ sparks appear 
synchronized by the action potential thereby establishing a uniform Ca2+ transient. Ca2+ 
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sparks that occur during diastole are totally normal but if the frequency of these sparks 
increases this leads to a severe SR Ca2+ leak which increases the probability of 
arrhythmias (Wehrens et al., 2003). Ca2+ release can be mediated by sympathetic 
activation of ß-adrenergic receptors. Activation of ß-receptors by epinephrine or 
norepinephrine activates GTP-binding proteins leading to cAMP production by adenylyl 
cyclases. cAMP in turn activates proteinkinase A and the kinase phosphorylates 
several proteins involved in EC-coupling thereby enhancing their function. Among 
these proteins are the DHPR, the RyR2, phospholamban, a negative regulator of 
SERCA, the myosin binding protein C and troponin I. This leads to enhanced Ca2+ 
influx through the DHPR, increased SERCA function leads to increased SR Ca2+ 
content and therefore to increased available Ca2+. All these effects enhance the Ca2+ 
transient amplitude. 
1.8.2 Influences of abnormal T-tubule structure in cardiomyocytes 
As in skeletal muscle, a highly organized T-tubule structure is also important in 
cardiomyocytes as disorganized T-tubule structure or loss of T-tubules involves 
impaired Ca2+ homeostasis presenting as desynchronized and impaired Ca2+ transients 
(Lyon et al., 2009, Louch et al., 2006) and may lead to acute heart failure. As 
mentioned above, many proteins have been found to be involved in biogenesis of the 
skeletal muscle T-tubule system. So far, much less is known about the role of these 
proteins in biogenesis of the cardiac T-tubule system and the maturation of the cardiac 
T-tubule system at all. Junctophilin 2 and Bin1 are the first proteins implicated in this 
process. Junctophilin 2, the cardiac isoform of junctophilin is required for normal 
structure of cardiac dyads and absence of the protein leads to reduced and unstable 
Ca2+ transients (Takeshima et al., 2000). Later it was demonstrated that junctophilin 2-
deficiency leads to acute heart failure due to disruption of the T-tubule structure (Van 
Oort et al., 2011). This leads to impaired coupling of RyR and DHPR and therefore 
alteration of Ca2+ homeostasis due to reduced Ca2+-induced Ca2+ release. Bin1 is also 
expressed in heart muscle and deficiency of the protein leads to hypertrophic 
cardiomyopathy and therefore prenatal lethal Bin1-deficient mice (Muller et al., 2003). It 
was demonstrated that Bin1 is responsible for trafficking of critical Ca2+ handling 
proteins, for example the DHPR, to the dyads in cardiamyocytes (Hong et al., 2010). In 
failing cardiomyocytes Bin1 expression is significantly decreased and knockdown of 
Bin1 leads to severely altered Ca2+ transient amplitudes in mouse cardiomyocytes 
(Hong et. al., 2012). Interestingly, the protein is involved in a process called “reverse 
remodeling” of the T-tubule system in hearts after recovery from heart failure (Lyon et 
al., 2012). This indicates that Bin1 and junctophilin 2 are involved in Ca2+ homeostasis 
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in cardiomyocytes. Its role in T-tubule biogenesis in cardiomyocytes remains to be 
investigated. 
1.9 Abnormal Ca2+ handling in muscular dystrophy 
In several studies it was demonstrated that the presence of muscular dystrophy can 
also have influences on Ca2+ homeostasis of muscle fibers. Dystrophin-deficient mdx 
mice show increased sarcolemmal Ca2+ permeability which leads to accumulation of 
Ca2+ in the cytosol and this activates proteases and induces necrosis of muscle fibers. 
The mechanism of Ca2+ entry is still under debate. It was discussed that Ca2+ enters 
through microtears due to instability of the plasma membrane or by a more active 
mechanism involving nonselective cation channels (Fong et al., 1990) or 
mechanosensitive channels (Franco et. al., 1990). Also SOCE seems to be increased 
in mdx muscle (Edwards et al., 2010). SOCE is activated upon SR Ca2+ store depletion 
which could be due to increased SR Ca2+ leak. Wang et al. demonstrated that 
dystrophic mdx muscle reveals an increased SR Ca2+ spark frequency which is 
probably due to membrane deformation (Wang et al., 2005). Additionally a reduced 
SERCA1 activity has been detected in mdx mice which probably further increases 
intracellular Ca2+ levels (Kargacin et al., 1996). It was demonstrated that 
overexpression of SERCA1 enhances SR Ca2+ uptake thereby decreasing intracellular 
Ca2+ levels and this leads to improvement of muscular dystrophy in these muscles 
(Goonasekera et al., 2011). Decreased SERCA activity in combination with increased 
Ca2+ sparks and following increased SOCE probably leads to increased intracellular 
Ca2+ levels which result in the dystrophic phenotype. Similar findings have been 
published for ß sarcoglycan-deficient mice, which show decreased exercise capacity 
due to increased RyR Ca2+ leak resulting in decreased Ca2+ release (Andersson et al., 
2012). These results clearly indicate that muscular dystrophy in skeletal muscle 
influences intracellular Ca2+ homeostasis.  
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2. Aim of the study 
This thesis aims to identify the cellular function of dysferlin and its role in the pathology 
of dysferlin-deficient muscular dystrophy. So far direct evidence of the main cell 
biological role of dysferlin is missing and therefore the main function of the dysferlin 
protein is still unknown. Mediation of plasma membrane repair was shown to be one 
function of dysferlin but as dysferlinopathy patients are without symptoms and have a 
high level of fitness until their second decade of life, this can not be the whole basis of 
the disease. Furthermore, overexpression of myoferlin in dysferlin-deficient mice 
rescues plasma membrane repair but does not alter the development of muscular 
dystrophy (Lostal et al., 2012). The association of the dysferlin protein to the 
developing T-tubule system and the finding that dysferlin-deficient mouse muscle is 
characterized by a highly abnormal configured T-tubule system (Klinge et al., 2010) 
suggested a functional role in the biogenesis of the T-tubule system. The fact that 
dysferlin shows high homology to Fer1, a protein mediating vesicle fusion and the fact 
that dysferlin contains several C2 domains, which are known to mediate phospholipid 
binding support a role of the protein in T-tubule development and further hint towards a 
role of dysferlin in membrane organization. Previous unpublished work demonstrated 
that dysferlin is able to induce membrane tubules upon heterologous expression in 
non-muscle cells and that these tubules are a newly induced membrane networks. This 
finding further supported the hypothesis that dysferlin is involved in membrane 
organization. In this thesis, the cellular and biochemical function of dysferlin with 
respect to membrane organisation and its role in tubule formation was investigated. 
The aims of this thesis were as follows: 
 
 Cellular investigation of dysferlin, truncated dysferlins and pathogenic dysferlin 
mutants in muscle and non-muscle cells with respect to localization and 
function and comparison to other ferlins. 
 Analysis of T-tubule- and triad-associated protein expression to detect potential 
alterations due to the abnormal T-tubule morphology 
 Biochemical analysis of membrane binding and membrane tubulation properties 
of the dysferlin full-length protein, truncated or mutated dysferlin proteins and 
single C2 domains 
 Identification of dysferlin localization in cardiomyocytes and potential influences 
of dysferlin-deficiency on the cardiac T-tubule system 
 Investigation of potential influences of dysferlin-deficiency and abnormal T-
tubule structure on cardiac and skeletal muscle Ca2+ homeostasis  
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Dysftm1Kcam mice were provided by Kate Bushby (Newcastle, UK; Bansal et al. 2003). 
Mdx mice were provided by Jens Schmidt (UMG). Male Dysftm1Kcam mice, mdx mice and 
respective age matched wild-type controls were used. All animals received human care 
in accordance with the institution’s guidelines, the German Convention for Protection of 
Animals and the National Institutes’ of Health guidelines. 
3.1.2 Cell culture 
 
Mammalian cell lines 
Cos 7 green monkey kidney, fibroblast-like cells 
HeLa human cervical cancer cell line 
C2C12  mouse myoblast cell line 
 
Mammalian cell culture medium 
DMEM (PAA Laboratories)  
10 %  Fetal calf serum (FCS) 
1 %  Penicillin/streptomycin 
1 % L-glutamine 
 
Freezing medium 
DMEM high glucose 
20 %  FCS 
1 %  Penicillin/streptomycin 
1 %  L-glutamine 
10 %  Dimethyl sulfoxide (DMSO) 
 
Transfection reagent 
Effectene Transfection Reagent   Qiagen 
 
0.05 % Trypsin    PAA Laboratories 
Phosphate buffered saline (PBS)  PAA Laboratories 
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BIOBlue Chemically Competent Cells  Bioline 
BL21-RIL (DE3)     Stratagene 
BL21-RIL star (rosetta plasmid)  provided by Achim Dickmanns (UMG) 
  
Bacterial culture media 
Bacterial media were autoclaved and supplemented with antibiotics prior to use. 
LB Medium and LB Agar were purchased from Roth. 
 
Antibiotics 
Kanamycin      25 mg/ml 
Ampicillin      100 mg/ml 
Chloramphenicol     30 mg/ml 
3.1.4 Molecular cloning 
 
Vectors and constructs 
 
Vectors 
Vector name         Purchased from 
pcDNA4/TO/myc His B         Invitrogen 
PST884/pET41a        Novagen 
pGEX6p1         GE Healthcare 
pGEX6p2          GE Healthcare 
 
Constructs 
Construct name Genotype    Provided by  
pcDNA4-GFP mammalian expression vector  AG Klinge  
containing GFP 
pcDNA4-GFP-DYSfl    GFP-tagged dysferlin   AG Klinge 
pcDNA4-GFP-Dysfl-Mut-1 (G299W) GFP-tagged dysferlin   AG Thoms/Klinge 
mutation in C2B domain 
pcDNA4-GFP-Dysfl-Mut-2 (R959W) GFP-tagged dysferlin   AG Thoms/Klinge 
mutation in C2C domain 
pcDNA4-GFP-Dysfl-Mut-3 (R1331L) GFP-tagged dysferlin containing AG Thoms/Klinge 
mutation not within C2 domain 
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pcDNA4-GFP-Dysfl-Mut-4 (L1341P) GFP-tagged dysferlin   AG Thoms/Klinge 
mutation in C2C domain 
pcDNA4-GFP-Dysfl-V67D   GFP-tagged dysferlin    this thesis 
mutation in C2A domain 
pcDNA4-Dysfl-Myc/His6   C-term Myc/His6-tagged dysferlin  AG Thoms/Klinge 
pcDNA4-His6-Dysfl     N-term His6-tagged dysferlin   AG Thoms/Klinge 
pcDNA4-GFP-C2FG    GFP-tagged truncated dysferlin  this thesis 
pcDNA4-GFP-C2FGTM   GFP-tagged truncated dysferlin  this thesis 
pcDNA4-GFP-DysΔTM   GFP-tagged dysferlin    AG Thoms/Klinge 
without TM domain 
pcDNAa-GFP-Minidysferlin  GFP-tagged truncated dysferlin  Martin Krahn, 
         (France) 
pcDNA4-GFP-Minidysferlin3   GFP-tagged truncated dysferlin  this thesis 
ECFP-N1-mOtoferlin-eGFP  C-term. GFP-tagged otoferlin  Ellen Reisinger, 
          (UMG) 
pcDNA3.1-Myoferlin-HA   N-term. HA-tagged myoferlin  Addgene  
pET41aΔN-B-His6-Dysfl  E.coli Expression vector  this thesis 
     containing N-term. His6-tagged dysferlin 
pGEX6p1-GST-Dysfl    E.coli Expression vector   this thesis 
containing N-term. GST-tagged dysferlin 
pET41aΔN-B-His6-DysflV67D   N-term. His6-tagged dysferlin  this thesis 
mutation in C2A domain 
pET41aΔN-B-His6-DysΔTM   N-term. His6-tagged dysferlin    this thesis 
without TM-domain 
pGEX6p1-Minidysferlin3  GST-tagged truncated dysferlin  this thesis 
pGEX6p1-C2A-Kl1    GST-tagged C2A domain  this thesis 
pGEX6p1-C2B-Kl1    GST-tagged C2B domain   this thesis 
pGEX6p1-C2C-Kl1    GST-tagged C2C domain   this thesis 
pGEX6p1-C2D-Kl1    GST-tagged C2D domain   this thesis 
pGEX6p1-C2E-Kl1    GST-tagged C2E domain  this thesis 
pGEX6p1-C2F-Kl1    GST-tagged C2F domain   this thesis 
pGEX6p1-C2G-Kl1    GST-tagged C2G domain   this thesis 
pGEX6p1-C2A-V67D    GST-tagged mutated C2A domain  this thesis 
pGEX6p2-Bin1     GST-tagged Bin1   this thesis 
GFP-Rab7     GFP-tagged Rab7   Addgene  
PH-ACT-YFP    YFP-tagged PH-ACT (PIP sensor) 
PH-PLC-GFP    GFP-tagged PH-PLC (PIP sensor) 
RFP-PIP2-kinase    PIP2 kinase 
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Enzymes and buffers 
Enzymes and buffers for restriction digestion were purchased from NEB. 
Pfu DNA polymerase   Promega 
Precisor DNA polymerase  BioCat 
T4 ligase     Fermentas 
Proteinase K    Qiagen 




50 mM     Tris/HCl (Roth), pH8.0 
10 mM     EDTA (Roth) 
100 μg/ml     RNAseA (Calbiochem) 
 
Buffer P2 
200 mM     NaOH 
1 % (v/v)    SDS (Roth) 
 
Buffer P3 
3 M      Potassium acetate, pH 5.5 
 
Lysis buffer for genotyping 
50 mM     Tris, pH 8 
100 mM     NaCl (Roth) 
1 % (v/v)    SDS 
1 mM      EDTA 
 
Agarose gel electrophoresis 
GeneRuler DNA Ladder Mix   Fermentas 
 
Agarose gel 
1 % agarose (Bioline), 0.5 μl / 80 ml GelRed (Biotium) in TAE-buffer 
 
TAE-Puffer: 
40 mM     Tris-HCl, pH 8.0 
0.1 % (v/v)     Acetic acid 
1 mM      EDTA 
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Oligonucleotides 
 
Primer name    Sequence      
 
Primers for genotyping 
P1 sense    5’-GCCAGACAAGCAAGGTTAGTGTGG-3’ 
P2 antisense    5’-GCGGGCTCTCAGGCACAGTATCTGC-3’ 
P3 antisense    5’-GCTGACTCTAGAGCTTGCGGAACC-3’ 
 
Sequencing primers 
pGEX 5’ primer (Invitrogen)  5’-GGGCTGGCAAGCCACGTTTGGTG3’   
pGEX 3’ primer (Invitrogen)  5’-CCG-GGAGCTGCA TGT GTC AGAGG-3’   
T7 promoter primer (Novagen) 5'-TAATACGACTCACTATAGGG-3' 
T7 terminator primer (Novagen) 5'-GCTAGTTATTGCTCAGCGG-3' 
 
Sequencing primers dysferlin 
IC1     5’-GCT CAG CTG ACG GAT GAG C-3‘ 
IC2     5’-GAT CTC AGC CAA ATG GAA GC-3' 
IC3     5’-CTC TTC ATG GAA GTG ATG C-3' 
IC4     5’-GCA GCC AGA CAT CGA GC-3' 
IC5     5’-CAG CCA AGA AGT GCT CCT TGG-3' 
OST583    5’-CAA AGC GGA GGC CCG C-3' 
OST584    5’-GCA ACC TGC TCC GGC C-3' 
OST585    5’-CAG GCT TCC CAG ACC C-3' 
OST586    5’-GGG GAC ACC GGG CCT C-3' 
OST587    5’-CCG CCC AGC ATT GTG G-3' 
OST602    5’-CCT GTG GTG GGC GAG TG-3' 
OST603    5’-CAT CCC CTG CAC GCT GG-3' 
OST604    5’-CCT GGA TGA CCT GAG C-3' 
 
Primer for mutagenesis 
OST 616, ΔTM mutation, sense 5’-CATGAAGTTCATCCTGTGACGGCGTTTCCG 
GTGGG-3' 
OST 617, ΔTM mutation, antisense 5’-CCCACCGGAAACGCCGTCACAGGATGAACT 
TCATG-3’ 
OST 907, mutation V67D, sense 5’-CCAGGGCTCTGAGCTTCATGATGTGGTCAA 
AGACC-3' 
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OST 908, mutation V67D, 5’-GGTCTTTGACCACATCATGAAGCTCAGAGC 
antisense  CCTGG-3' 
JH12, truncated dysferlin, sense 5’-GTACCGAATTCATGGAGGAAGAGTTCA 
TCGAT-3' 
JH3, truncated dysferlin, antisense 5’-GTACCGCGGCCGCTCAGCTGAAGGG 
CTTCA-3' 
JH10, truncated dysferlin ΔTM, 5’-GTACCGCGGCCGCTCACCGGAAACG 
antisense    CCGCC-3' 
JH53, minidysferlin 3, sense  5’-CTAGAAAGCTGCTGTCAGACAAACCGCAGGT 
GATTGGTGAATTTAAGGGCCTCTTC-3' 





DpnI mediated mutagenesis 
10 ng   template DNA 
2.5 μl   10x Pfu DNA polymerase buffer 
1.5 μl   sense primer (10 μM) 
1.5 μl   antisense primer (10 μM) 
1.35 μl  dNTP mix (3.75 mM)  
0.5 μl   Pfu DNA polymerase 
ad 25 μl  ddH2O 
 
1. 95°C  30 s 
2. 95°C  30 s 
3. 55°C  1 min 
4. 68°C  2 min/kb of plasmid length 18 cycles 
5. 10°C  pause 
 
DpnI digest 
25 μl   PCR product  
1 μl   DpnI 
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Sequencing PCR 
0.2-0.3 μg  DNA 
0.5 μl   primer (10 μM) 
2 μl   BigDye 5x Sequencing buffer (Applied Biosystems) 
1 μl   BigDye Sequencing Ready Reaction Premix (Applied Biosystems) 
ad 10 μl  ddH2O 
 
1. 96°C 10 s 
2. 60°C 4 min / 24 cycles 
3. 10°C  pause 
 
Genotyping PCR 
5 μl   5x GC buffer  
0.13 μl  MgCl2 (50 mM) 
1.4 μl  dNTPs (3.75 mM) 
0.5 μl  primer P1 (10 μM) 
0.5 μl  primer P2/P3 (10 μM) 
0.25 μl  Precissor polymerase 
ad 25 μl ddH20 
 
1. 98°C 3 min 
2. 98°C 30 s 
3. 65°C 30 s 
4. 72°C 90 s / 34 cycles 
5. 72°C 5 min 
6. 4°C pause 
 




12.5 mM  Sucrose 
0.3 mM NaN3 
10 mM  NaHCO3, pH 7.0 
0.1 mM Phenylmethylsulfonyl fluoride (PMSF, AppliChem) 
Complete protease inhibitors (Roche) 
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TBST 
200 mM  Tris  
1.5 M  NaCl 
1 % (v/v) Tween 20  
 
Blocking Solution 
4 % (w/v) non fat dry milk powder in TBST 
 
Blotting buffer 
48 mM  Tris  
39 mM  Glycin (Roth) 
0.04 % (v/v)   SDS  
10 % (v/v) MeOH (J.T.Baker) 
 
Sample Buffer (4x) 
160 mM Tris/HCl pH6.8 
8 % (v/v) SDS 
20 % (v/v) Glycerol (Sigma) 
0.01 g  Bromphenolblue (Merck) 
100 mg/ml  DTT (Serva) 
 
SDS running buffer 
3.03 g   Tris 
14.4 g   Glycine 
50 ml   20 % SDS 
Ad 1000ml dH2O 
 
8 %/12 % SDS separating gel 
8 %/12 % (v/v)Polyacrylamide (BioRAD) 
0.39 M  Tris/HCl, pH 8.8  
0.1 % (v/v) SDS  
0.1 % (v/v) Ammonium persulfate (Roth) 
0.1 % (v/v) TEMED (Roth)  
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SDS stacking gel 
5.1 % (v/v) Polyacrylamide  
0.13 M  Tris/HCl, pH 6.8 
01 % (v/v) SDS  
0.1 % (v/v) Ammonium persulfate  
0.1 % (v/v) TEMED  
 
Protein ladders 
PageRuler Prestained Protein Ladder Thermo 
PageRuler Plus Prestained Protein Ladder Thermo 
 
Detection 
Lumi-Light western blot substrate   Roche 
 
Transfer membrane 




Lysis buffer  
300 mM NaCl in PBS, pH 7.3 
 
Washing buffer 
2 mM 2-mercaptoethanol (ß-ME) (Sigma) in lysis buffer 
 
Elution buffer 
50 mM  Tris/HCl, pH 8 
150 mM  NaCl 
10 mM  reduced Glutathione (Sigma) 
2 mM   ß-ME 
 
Lysis-buffer C2 domains 
20 mM  Tris/HCl pH 7.4 
150 mM  NaCl 
3 mM   DTT  
0.4 % (v/v)  Triton X-100 
0.4% (w/v) Sodium-deoxycholate 
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8 M urea-buffer 
20 mM  Tris/HCl, pH 7.4 
150 mM  NaCl 
3 mM   DTT 
8 M   Urea 
 
1 M NDSB201 
20 mM  Tris/HCl pH 7.4 
150 mM  NaCl 
3 mM   DTT  
1 M  NDSB201 
 
Complete protease inhibitors without EDTA  in PBS, Roche 
Lysozyme 10mg/ml     Roche 
PMSF       in isopropanol, AppliChem 
DNAse 50 U/μl      Affimetrix 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) in H2O, Sigma 
Glutathione Sepharose 4B    GE Healthcare 
 
Antibodies for Western Blot and Immunofluorescence 
 
Antibody   Dilution   Application Species Company  
RYR (sc-13942)  1:200  WB  rabbit  Santa Cruz 
DHPR (sc-103588)   1:100  IF  goat  Santa Cruz 
Dysferlin (ab15108)   1:500  WB  rabbit  Abcam 
Dysferlin (NCL-Hamlet) 1:500/1:50 WB/IF  mouse  Novocastra 
Amphiphysin II (sc-13575) 1:500  WB  mouse  Santa Cruz 
Mitsugumin (ab106438) 1:1000  WB  rabbit  Abcam 
SERCA (ab2818)  1:2500  WB  mouse  Abcam 
Junctophilin 2 (PA5-20640) 1.1000  WB  rabbit   Thermo 
STIM1 (610954)  1:250  WB  mouse  BD Biosciences 
FKBP12 (ab24373)   1:1000  WB  rabbit  Abcam 
TRPC3 (ab51560)   1:1000  WB  rabbit  Abcam 
Orai1 (ab59330)   1:200  WB  rabbit  Abcam 
PMCA (ab2825)   1.1000  WB  mouse  Abcam  
anti HA (sc-7392)   1:50  IF  mouse  Santa Cruz 
anti Lamp1 (ab24170)  1:600  IF  rabbit  Abcam 
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anti Golgi (ab27043)   1:100  IF  mouse  Abcam 
anti PDI (ab27092)   1:1000  IF  mouse  Abcam 
anti Pex14 (10594-1-AP) 1:100  IF  mouse  Proteintech  
anti MYC (sc-789)  1.100  IF  rabbit  Santa Cruz 
Cy3 anti rabbit   1:100  IF  goat  Jackson 
Cy3 anti mouse   1:100  IF  donkey Jackson 
Cy3 anti goat   1:100  IF  donkey Jackson 
AlexaFluor 488 anti rabbit 1:100   IF  goat  Life technologies  
AlexaFluor 488 anti mouse  1:100  IF  donkey Life technologies 
Anti rabbit HRP  1:10000 WB  goat  Dianova 
Anti mouse HRP  1:10000 WB  donkey Dianova 
 
3.1.6 Immunofluorescence  
 
PBS  
8 g  NaCl 
0.2 g  KCl 
1.44 g  Na2HPO4 x 2H2O 
0.24 g  KH2PO4 
pH 7.4 
 
Fixative for Cos7/HeLa cells 
4 % (v/v) Paraformaldehyde (PFA) in PBS   Affimetrix 
 
Fixative for cardiomyocytes 
100 % (v/v) Ethanol     Merck 
 
Blocking Solution for Cos7/HeLa cells 
5 %(w/v) BSA (Roth) and 0.5 % (w/v) Triton (Roth) in PBS 
 
Blocking solution for cardiomyocytes 
3 % (v/v) Horse serum (Gibco), 0.5 % (v/v) Saponin, in PBS 
 
Mounting medium 
Vectashield Mounting Medium with DAPI   Vector Laboratories 
Vectashield HardSet Mounting Medium with DAPI  Vector Laboratories 
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Chemical compounds 
Phalloidin      Santa Cruz 
Cytochalasin D in DMSO    Tocris 
FM4-64 1 mM in DMSO     MoBiTec 
Di8ANEPPS      provided by Viacheslav Nicolaev  
       (UMG) 
 
3.1.7 SDH staining 
 
SDH solution 
0.216 mg Sodium succinate 
0.024 M  Na2HPO4 x 2H20 
0.024 M  KH2PO4, pH 7.4 
8 mg  Nitroblue tetrazolium 
10 mM  MgCl2 
2.5 mg  Menadione 
 
3.1.8 Electron microscopy and liposome experiments 
Phosphotungstic acid hydrate in H2O  Fluka 
Extruder     provided by Tolga Soykan   
    (MPI for Experimental Medicine,  
    Göttingen) 
Membranes (100 nm)     Echelon 
Lipids       Avanti polar lipids, Echelon 
Brain extract from bovine brain, type 1  Sigma  
Pip Strips      Echelon 
Carbon/formvar coated copper grids   Polysciences 
 
Hydration solution for tubulation experiments 
30 mM  Tris pH 7.4 
150 mM  NaCl 
300 mM  Sucrose 
1 mM   EDTA 
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Hydration solution for flotation experiments 
20 mM  Tris pH 7.4 
100 mM  NaCl 
150 mM  Sucrose 
1 mM   EDTA  
 
Sucrose-solution 
0.25 - 2 M Sucrose in hydration solution for flotation experiments containing 1 mM 
CaCl2. 
 
3.1.9 Ca2+ imaging 
 
Caffeine    Sigma 
Fura-2 (AM)    in DMSO, MoBiTec 
Fluo-4 (AM)    in DMSO, Invitrogen 
BTS      in DMSO, Sigma 
Laminin    Sigma 





113 mM  NaCl,  
4.7 mM KCl 
0.6 mM KH2PO4 
0.6 mM  MgSO4 x 7H2O 
1.2 mM  Na2HPO4 x 2H2O 
0.032 mM Phenol-red 
12 mM  NaHCO3 
10 mM  KHCO3 
10 mM  HEPES  
30 mM  Taurine 
5.5 mM  Glucose  
10 mM  BDM 
pH 7.42 
Material and Methods  31 
Enzyme solution 
0.075 mg/ml Liberase 
0.014 % Trypsin 
0.013 mM CaCl2 
in isolation solution 
 
Stop solution 
10 % Bovine calf serum and 0.013 mM CaCl2 in isolation solution 
 
Solution for Ca2+ reintroduction 
5 % Bovine calf serum containing 0.1 - 1.6 mM CaCl2 in isolation solution 
 
Tyrode’s solution with Ca2+ 
140 mM  NaCl 
5.4 mM  KCl 
1 mM   MgCl  
5 mM   Hepes 
10 mM  Glucose 
1 mM   CaCl2 
pH 7.54 
 
Tyrode’s solution without Ca2+ 
140 mM  NaCl 
5.4 mM KCl 
1 mM   MgCl2  
5 mM   HEPES 
10 mM  Glucose 
pH 7.54 
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Fluo-4 calibration solution 
135 mM  LiCl 
2 mM   MnCl2 
10 mM  Caffeine 
10 mM  BDM 
1 mM   Ouabain 
10 μM   Ionomycin 




10 mM Caffeine in Tyrode’s solution without Ca2+  
 
ASC-Tyrode with isoprenaline 
1 l   Tyrode´s solution with Ca2+ 
50 mg   Ascorbic acid 
5 μl  HCl (32 %) 
10-7 M  Isoprenaline 
 
Fluo-4 staining solution 




Ringer’s solution with Ca2+ 
145 mM  NaCl 
2.5 mM  KCl 
10 mM  HEPES 
1 mM   MgSO4 x 7H2O 
10 mM  Glucose  
2 mM   CaCl2 x 2H2O 
pH 7.4  
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Ringer’s solution without Ca2+ 
145 mM  NaCl 
2.5 mM  KCl  
10 mM  HEPES 
1 mM   MgSO4 x 7H2O 
10 mM  Glucose 
0.5 mM  EGTA 
pH 7.4 
 
Hypotonic solution for spark measurements 
Ringer’s solution with Ca2+ containing 70 mM NaCl (instead of 145 mM) 
 
Collagenase-solution  
4 mg/ml Collagenase type 2 (Worthington) in Ringer’s solution with Ca2+ 
 
Caffeine-solution  
30 mM Caffeine in Ringer’s solution without Ca2+ 
 
Fura-2 staining solution 





Axioimager M1 (Zeiss) equipped with a Plan Neofluar 100x/1.3 Oil lens. 
AxioCam HRm (Zeiss) and Axiovision 4.8 software (Zeiss) were used for acquisition. 
 
Laser scanning confocal microscope for immunofluorescence imaging 
LSM 710 (Zeiss); ZEN 2009 software (Zeiss) 
 
Laser scanning confocal microscope for measurement of Ca2+ sparks 
LSM 5 Pascal, Zeiss; analysis by Image J 
 
Electron microscope 
LEO EM912 Omega (Zeiss) with on-axis 2048x2048-CCD camera (Proscan) 
Material and Methods  34 
Epifluorescence microscope for measurement of Ca2+ transients 
Microscope, Nikon Eclipse TE300  
Optical setup, IonWizard 
 
Analysis of Ca2+ transients 
IONWizard Analyze Version 5.0 (ION OPTIX) 
 
Analysis of Ca2+ sparks 
Image J analysis software /Plug In SparkMaster (NIH) 
 
Western Blot detection 
Luminescent image reader LAS-4000 mini (Fujifilm) 
 
Sonifier UP 50H (Hielscher) 
Tissue Ruptor (Quiagen) 
 
Centrifuges 
Beckman coulter CC-GPKR 
Eppendorf centrifuge 5424 
Optima TL centrifuge, TLA 100.2 rotor 
RC-5 centrifuge (Sorvall) Thermo Fisher, GSA rotor 
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3.2 Methods 
3.2.1 Genotyping of mice 
Mouse tails were incubated in 350 μl lysis buffer with 60 μg proteinase K (2 mg/ml) 
over night at 55 °C in a shaker. The DNA was extracted with 400 μl phenol/chloroform 
at room temperature. The mixture was shaken 60 times and centrifuged 3 min at 
10000 rpm at room temperature. The supernatant was transferred into a new e-cup 
and phenol/chloroform extraction was repeated. The supernatant was again transferred 
into a new e-cup and DNA was extracted with 300 μl chloroform. The DNA was 
precipitated by adding 600 μl 100% ethanol and 30 μl 3M sodium acetate pH 6.0 and 
washed with 70 % ethanol. The pellet was dried and resuspended in 30 μl dH2O. 
Genotyping PCR was performed with Precissor Polymerase. Primers P1 and P2 
amplify a 3.4 kb fragment from the WT allele and primers P1 and P3 amplify a 3 kb 
fragment from the KO allele only (Bansal et al., 2003). 
3.2.2 Molecular cloning 
3.2.2.1 Manipulation of DNA 
For restriction digestion 1 μg of DNA was digested with 0.2 to 0.3 μl enzyme at 37 °C 
for required times. The DNA was purified by High Pure PCR Product Purification Kit 
(Roche) or was extracted from agarose gel by NucleoSpin Extraction Kit (Macherey-
Nagel). Ligation was carried out by mixing 50 ng of vector-DNA with three-fold molar 
mass of insert-DNA with 1 μl of T4-ligase and 2 μl 10x ligase buffer and added with 
dH2O to a final volume of 20 μl. Blunt ligation was carried out at room temperature for 
60 min and sticky end ligation at room temperature for 20 min. The ligation mix was 
directly used for transformation. 
3.2.2.2 Transformation  
An aliquot of competent cells was thawed on ice and 1 μl of ligation mix was added to 
10 μl of competent cells and incubated on ice for 20 min. A short heat pulse at 42°C 
(70 s) was given and the cells were incubated on ice for another 10 min. The cells were 
suspended in LB medium without antibiotics and incubated at 37 °C for one hour in a 
shaker and were then plated on LB plates containing appropriate antibiotics. The plates 
were incubated over night at 37 °C and single colonies were picked with a sterile 
pipette tip and incubated over night in 3 ml LB-medium with antibiotics. 
3.2.2.3 Plasmid purification 
For Mini plasmid purification single colonies were incubated over night in 3 ml LB 
medium containing appropriate resistance and were then centrifuged for one min at 
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8000 rpm. The supernatant was discarded, the pellet was resuspended in 200 μl buffer 
P1 and 300 μl buffer P2 was added and the sample was inverted and incubated for 
5 min at room temperature. 300 μl buffer P3 was added, the sample was inverted and 
centrifuged for 10 min at 14000 rpm. The supernatant was transferred into a new e-cup 
and the DNA was precipitated with 0.7 volumes of isopropanol and 20 min 
centrifugation at 14000 rpm. The pellet was washed with 70% ethanol, dried for 10 min 
at 37 °C and resuspended in 30 μl dH20. 
For Midi plasmid purification 100 ml LB-medium was inoculated with 100 μl of overnight 
culture. The cells were harvested by 20 min centrifugation at 3000 rpm and preparation 
of DNA was done according to the manufacturers protocol (Macherey-Nagel) and DNA 
was eluted from columns with dH2O. 
3.2.2.4 DNA sequencing 
DNA sequencing was done with BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems) according to the manufacturers instructions. For purification of the cycle 
sequencing product 220 μl 100 % ethanol, 120 μl H2O and 10 μl 3 M sodium acetate 
(pH 4.6) was added, the mix was vortexed and incubated for 15 min at room 
temperature and centrifuged for 20 min at 14000 rpm. The pellet was washed with 
70 % ethanol, dried and resuspended in 10 μl formamide. DNA sequencing was done 
by Andreas Ohlenbusch (Department of Pediatrics, UMG) by sanger sequencing (DNA-
sequencer ABI AVANT 3100, Advanced Biolab). 
3.2.2.5 Expression constructs 
Several dysferlin constructs for mammalian expression have been already available in 
my group. These included a GFP-dysferlin construct (pcDNA4-GFP-Dysfl) which had 
been cloned into EcoRI and NotI sites of pcDNA4/TO/myc His B-vector, an N-terminal 
His6-tagged construct (pcDNA4-His6-Dysfl) and a C-terminal myc-tagged construct 
(pcDNA4-Dysfl-Myc/His6). For cloning of a bacterial expression construct of dysferlin 
(pET41aΔN-B-His6-Dysf), the pET41a vector was cleaved by NdeI and BglII and 
klenow fill-in with following blunt ligation was performed to delete the GST tag from the 
vector. N-terminal his-tagged dysferlin was then inserted into KpnI and NotI sites of the 
vector. Furthermore, four dysferlin constructs containing pathogenic mutations have 
already been available. A further patient mutation, mutation V67D, was introduced into 
dysferlin-constructs pcDNA4-GFP-Dysfl and pET41aΔNB-His6-Dysfl by DpnI 
mutagenesis using primers OST907 and 908 (C2A mutant). For degradation of 
methylated parental DNA the PCR product was cleaved with 8 u DpnI at 37°C for one 
hour and was then transformed into BIOBlue Chemically Competent Cells. Positive 
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clones were identified by sequencing. The transmembrane mutant pET41aΔN-B-His6-
DysflΔTM was also generated by DpnI mutagenesis with primers OST616 and 617. 
Three truncated dysferlin constructs were cloned. Two truncated constructs contain 
only the last two C2 domains with or without (C2FG) the transmembrane domain. They 
were amplified by primers JH12 and JH3 (with transmembrane domain) or JH10 
(without transmembrane domain) and introduced into EcoRI and NotI sites of pcDNA4-
GFP-vector. The pcDNA4-GFP-minidys3 was generated by DpnI mutagenesis with 
primers JH53 and JH 54 using pcDNA4-GFP-dsyfl as template (Azakir et al., 2012) The 
minidysferlin 3 was then cloned into EcoRI and NotI sites of pGEX6pI vector and 
pcDNA4-GFP vector. pGEX4T1-C2A to C2G were kindly provided by Michael 
Sinnreich (University of Montreal, Canada). The C2 domains were cloned into EcoRI 
and NotI sites of pGEX6p1 vector. pGEX6p1-C2A-V67D was generated by DpnI 
mutagenesis with pGEX6p1-C2A and primers OST 907 and 908. Bin1 (kindly provided 
by Pietro de Camilli, University of Yale, USA) was cloned into BamHI and NotI sites of 
pGEX6p2-vector. All constructs were verified by DNA sequencing. 
3.2.3 Western Blotting 
For Western Blot of mouse muscle homogenates, the quadriceps femoris muscle was 
isolated from young (9-11 weeks) and old (50-66 weeks) wild-type and knock-out mice 
and was frozen in liquid nitrogen and stored at -80°C. Muscle samples were 
homogenized in homogenization buffer with the tissue ruptor (Quiagen) and protein 
concentration was determined by BCA assay (Uptima). Samples were mixed with 4x 
sample buffer and incubated for 5 min at 95°C. 20 μg protein was loaded on 8-12 % 
SDS gels (depending on protein size) and transferred onto nitrocellulose membranes. 
Proteins were detected by antibodies listed above. For statistical analysis densitometry 
levels were determined using Image J analysis software and were normalized to 
GAPDH. 
3.2.4 Protein expression 
Proteins were cloned into bacterial expression vectors and transformed into competent 
BL21-RIL or BL21star/rosetta cells. A 50 ml overnight culture was grown in LB 
containing antibiotics. This culture was used to inoculate the main culture of 500 ml LB 
containing antibiotics. At an OD600 of 0.5 to 0.6 protein expression was induced by 
0.5 mM IPTG and the culture was incubated for 3 h at 30°C and vigorous shaking. The 
cells were harvested at 5000 rpm in a Sorvall GSM centrifugation rotor for 20 min, 
washed with cold PBS again centrifuged at 3000 rpm for 20 min and about 1 g of 
bacteria could be collected from a 500 ml culture. The cells were frozen at -80°C, 
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thawed on ice and per 1 g of pellet the cells were resuspended in 10 ml lysis buffer 
containing Complete Protease Inhibitors without EDTA, DNAse and 50 μg/ml lysozyme. 
The resuspended cells were rotated for 30 min at 4°C and the cell lysate was frozen in 
1 ml aliquots at -80°C.The lysate was thawed on ice and sonicated (ultrasonic 
processor, Hielscher) two times for 10 s with an amplitude setting of 30 %. Total cell 
lysate was verified by Western Blot and used for further experiments. Expression of 
Bin1 was done as described above. The cell lysate was then centrifuged at 42000 rpm 
for 50 min at 4°C and the supernatant was used for protein purification in batch via 
Glutathione sepharose 4B. Purification was done according to manufacturer’s protocol. 
The glutathione sepharose was washed 3 times with washing buffer and the protein 
was bound to the column material for 1 hour at room temperature on a rotating 
platform. The column was washed again 3 times and the protein was eluted with 
elution buffer. Expression of C2 domains was done as explained above; cells were 
harvested after 2 h induction at 30 °c. 1 g of cell pellet was resuspended in 10 ml 
lysis buffer for C2 domains containing Complete Protease Inhibitors without EDTA, 
DNAse and 50 μg/ml lysozyme and was rotated for 30 min at 4°C and the cell lysate 
was frozen in 1 ml aliquots at -80°C. Lysates were then thawed on ice, supplemented 
with 0.1 mM PMSF, 3 mM DTT, 0.4 % Triton X-100 and 0.4 % sodium deoxycholate 
and sonicated two times 10 s at 30 % amplitude. Inclusion bodies were pelleted for 
30 min. at max. speed at 4 °C. The pellet was washed and resuspended in 8 M urea-
buffer for 2 hours on a rotating platform at room temperature. Insoluble material was 
separated by centrifugation for another 30 min at 4 °C at max. speed. The soluble 
protein in the supernatant was then refolded by adding it drop-wise under constant 
agitation to 10 times the volume of 1M NDSB201 solution. To remove the urea from 
refolded protein, the sample was dialyzed two times against lysis buffer without 
detergents and concentrated afterwards. 
3.2.5 Liposome experiments 
For preparation of liposomes glass tubes were rinsed with chloroform, 10 μl Folch 
Fraction lipids (100 mg/ml) with or without 5 % PIP2, PI3P or NBD-labeled PE were 
added and evaporated with N2. Lipids were then hydrated with 750 μl hydration 
solution. The solution was added drop wise to the lipids with vigorous vortexing so that 
liposomes were formed. Liposomes were stored in the dark at 4°C. For liposome 
tubulation experiments liposomes were extruded 21 times through 100 nm membranes 
afterwards.  
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3.2.5.1 Liposome tubulation and electron microscopy 
For liposome tubulation experiments, 2.5 μl of protein lysate (10 µg/µl) and Bin1 protein 
(2 µg/µl) was added to 7.5 μl of liposomes in presence of 2.5 mM CaCl2 and the 
liposome protein mixture was incubated at 37°C for 20 min. Negative stain of 
liposomes was modified from the protocol of Brian Peter (lab of Harvey McMahon). The 
liposome-protein mixture was diluted 1:10 with hydration solution and 6 μl aliquots were 
absorbed onto formvar- and carbon-coated copper grids for 45 s, stained for 20 s with 
PTA, blotted and washed with hydration solution, blotted again, air dried and analyzed 
by electron microscopy. Binding of C2 domains to liposomes was carried out as 
described above using liposomes from Folch fraction lipids containing 5 % NBD-
labeled PE and analyzing them by fluorescence microscopy. 
3.2.5.2 Liposome flotation 
Liposome flotation assay was modified from Klopfenstein et al., 2004. 5 μl of Bin1 
protein (2 µg/µl) and 40 µl of dysferlin lysates (5 µg/µl) were added to 100 μl of 
liposomes in presence of 2.5 mM CaCl2 and the liposome protein mixture was 
incubated at 37°C for 20 min. 2 M sucrose-solution was added to the protein-liposome 
mixture to bring the final concentration to 1.6 M sucrose and the mixture was overlaid 
with 300 µl 1.4 M sucrose, 150 µl 0.4 M sucrose and 300 µl 0.25 M sucrose. Gradient 
centrifugation was carried out using a TLS55 rotor for 60 min at 4°C and 55000 rpm. 
200 µl fractions were taken and analyzed by SDS-PAGE and immunoblotting. 
3.2.5.3 PIP-strips 
PIP-strips were used according to manufacturer’s protocol. PIP-strips were incubated 
with 5 ml PI(4,5)P2 Grip™ protein (positive control, 0.5 µg/ml) or 500 µl Bin1 
(0.01 µg/µl) or dysferlin protein lysates (5 µg/µl) in 3 % BSA in TBST and detected by 
anti-GST (Bin1 and control protein) or anti-dysferlin (Hamlet) antibodies (dysferlin, 
minidysferlin 3 and C2A mutant) and chemiluminescence. 
3.2.6 Immunofluorescence staining 
For immunofluorescence staining of cell lines, cells were seeded on cover slips. The 
cells were washed two times with PBS, fixed with 4% PFA for 15 min and washed 
again with blocking solution. After incubation with blocking solution for 20 min the cells 
were incubated with the first antibody diluted in blocking solution for 1 h in a moist 
chamber at room temperature and washed three times 5 min with PBS. The cells were 
incubated with the second antibody in blocking solution (3 % horse serum, 0.5 % 
saponin in PBS) for 1 h in a moist chamber at room temperature, then washed again 
Material and Methods  40 
three times for 5 min and mounted with Vectashield mounting medium on a microscope 
slide. Plasma membrane staining with FM4-64 was carried out according to 
manufacturer’s instructions. Cells on cover slips were incubated for 60 s with 1 μM 
FM4-64 on ice, washed with PBS 1% PFA and imaged by confocal microscopy. For 
inhibition of actin cytoskeleton cells were incubated with 1 μM cyto D for 30 min at 
37°C (Shinozaki-Narikawa et al., 2006). 
For immunofluorescence staining of isolated cardiomyocytes cover slips were 
incubated with laminin mixture (40 μl laminin per 3 ml of PBS) for one hour for better 
cell adhesion. The cells were seed on the laminin-coated cover slips and incubated for 
one hour. The cells were fixed with ice-cold 100% ethanol at -20° for 20 min and 
washed three times 5 min with cold PBS. The cells were incubated with blocking 
solution (5 % BSA, 0.5 % Trition X-100 in PBS) for 1 h and incubated with the first 
antibody diluted in blocking solution at 4°C in a moist chamber overnight. The cells 
were washed with PBS for 10 min three times, incubated with the second antibody 
diluted in blocking solution for 1.5 h at room chamber in a moist chamber and mounted 
with Vectashield hard set mounting medium on a microscope slide. Cells were imaged 
by fluorescence or confocal microscopy.  
Di8ANNEPS staining was carried out by Viacheslav Nicolaev (Department of 
Cardiology, UMG). Isolated cardiomyocytes were seeded on laminin-coated cover 
slips, washed with PBS, stained with di8ANEPPS for 15 min and analyzed by confocal 
microscopy. 
3.2.7 SDH staining 
For SDH staining gastrocnemius muscles were isolated from wild-type and knock-out 
mice at the age of 8 or 13 to 17 weeks and muscles were embedded in mounting 
medium (Tissue-Tek), frozen in isopentane cooled in liquid nitrogen and stored at         
-80°C until later analysis. Sections were cut on a microtome and slices were again 
stored at -80°C. SDH staining was carried out using the nitroblue tetrazolium technique 
(Defendi and Pearson, 1955). Slices were pre-warmed at room temperature for 30 min, 
incubated for 30 min at 37°C in SDH staining solution and washed in H2O for 2 min. 
The slices were then fixed in 10 % formalin for 10 min and rinsed in H2O and mounted 
with Aquatex. 
3.2.8 Ca2+ imaging 
Ca2+ measurements were done in collaboration with the lab of Lars Maier (UMG, 
Department. of Cardiology). 
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3.2.8.1 Ca2+ imaging in cardiomyocytes 
3.2.8.1.1 Preparation of cardiomyocytes 
Cardiomyocytes from wild-type and dysferlin-null mice hearts were isolated by Timo 
Schulte (UMG, Department of Cardiology) as described in Backs et al., 2009. Hearts 
were excised from mice after isoflurane anesthesia and following cervical dislocation. 
Hearts were mounted on a Langendorff perfusion apparatus and perfused with isolation 
solution. Perfusion was then switched to enzyme solution for 7 min and hearts were 
removed, dissected and dispersed afterwards. Stop solution was added and the tissue 
was filtered through nylon gauze afterwards. Isolated cardiomyocytes were allowed to 
settle for 7 min, the supernatant was discarded and the cells were resuspended in 
isolation Tyrode containing 0.1 mM Ca2+ and were settled again. This step was 
repeated with isolation solution containing 0.2 mM, 0.4 mM, 0.8 mM and 1.6 mM Ca2+ 
for slow Ca2+ reintroduction. After the last step the cells were seed on laminin coated 
chambers with glass bottoms and incubated for 15 min at room temperature for settling 
of the cardiomyocytes. The cells were then incubated with 10 μM of the acetomethyl 
ester (AM) form of Fluo-4 in the dark at room temperature for 20 min for Ca2+ 
measurements and for 7 min for spark-measurements.  
3.2.8.1.2 Detection of intracellular Ca2+ transients and shortening 
Detection of Ca2+ transients was carried out by epifluorescence microscopy (ION 
OPTIX) at 37°C. The chamber was mounted on the microscope and cells were 
provided with a constant flow of 80 ml/h of Tyrode´s solution with Ca2+ using a 
superfusion system. The cells were rinsed with this solution for at least 10 min to 
remove excess dye from the chambers and to allow cleavage of AM groups from the 
dye by esterases and for another 10 min with a stimulation of 1 Hz to achieve a steady-
state. The image of the cells were detected by a camera (MyoCam) and displayed on a 
monitor. The Ca2+ indicator dye Fluo-4 AM was excited with a wave length of 488 nm 
using a 75 W xenon arc lamp on the stage of a Nicon Eclipse TE 200-U inverted 
microscope. Emitted fluorescence at 535 nm was measured using a photomultipier and 
shortening of the cells was measured using a sarcomere length detection system (Ion 
Optix Corp, Milton, Mass). Fluo-4 is a non-ratiometric dye; therefore the Ca2+ 
concentration is determined by a relative increase in fluorescence intensity due to 
elevations of free Ca2+ levels in the cytoplasm. Ca2+ transient amplitudes and 
shortening of the cells were measured at 0.5, 1, 2, 3 and 4 Hz. After subtraction of the 
background fluorescence, F/F0 was calculated by dividing the raw fluorescence (F) by 
the baseline fluorescence (F0). For measurement of stress induced differences in Ca
2+ 
release, the cells were provided with a constant flow of Tyrode’s solution with 
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isoprenaline and Ca2+ transients and shortening were measured again at 1 Hz. For 
measurement of SR Ca2+ content stimulation was stopped for 30 s and Ca2+ transients 
before and after rest were analyzed (post-rest relation). Furthermore, the Ca2+ content 
was measured by caffeine stimulated Ca2+-release. Stimulation was stopped and 
addition of Tyrode’s solution with caffeine evoked Ca2+ release from the SR. Analysis of 
Ca2+ transients and shortening was done with IONWizard Analyze Version 5.0 (ION 
OPTIX). Non-stimulated events were detected during measurement of Ca2+ transients 
and shortening during steady-state stimulation and when stimulation was paused. 
Analysis of non-stimulated events was done using the following semi quantitative 
arrhythmia score: single non-stimulated event: 1 point, bigeminy or trigeminus (coupled 
non-stimulated event): 2 points, couplet (two following non-stimulated events): 3 points, 
triplet (three following non-stimulated events): 4 points, salvo (four or more following 
non-stimulated events): 5 points, tachycardia (non-stimulated events following for more 
then 10 s): 6 points. 
3.2.8.1.3 Detection of Ca2+ sparks 
Detection of Ca2+ sparks was performed at room temperature by laser scanning 
confocal microscopy (LSM 5 Pascal, Zeiss) using a 40x oil-immersion objective. The 
chamber was mounted on the microscope and cells were provided with a constant flow 
of Tyrode’s solution with Ca2+. The cells were rinsed with this solution for at least 
10 min to remove excess dye from the chambers and to allow de-esterification. The 
Ca2+ indicator dye Fluo-4 AM was excited with an argon laser at 488 nm and emitted 
fluorescence was collected through a 515 nm long-pass filter. The protocol for spark-
measurement was as follows: Cells were measured with 0.25 Hz stimulation and after 
an unstimulated period of 30 s. Measurements were repeated with Tyrode’s solution 
containing isoprenaline. Measurements were done in “line-scan”-mode with a pixel time 
of 0.8 μs, a scan time of 960 μs, 510 pixel per line, a pixel size of 0.1 μm, a pixel depth 
of 12 bit, a scan width of 51 μm (zoom factor 4.5) and 4000 lines. Analysis of spark 
measurements was done with Image J plug in Sparkmaster (Picht et al., 2007). Ca2+ 
spark frequency (CaSpF) was normalized to cell width and scan time (μm-1*s-1). Peak 
of Ca2+ sparks was normalized to F/F0 (the raw fluorescence was divided by the 
baseline fluorescence after subtraction of the background fluorescence). Duration of 
the sparks was taken from the full-duration half maximum (FDHM) and width of the 
sparks from the full-width half maximum (FWHM). The Ca2+ spark volume was 
calculated from duration, width and amplitude of the sparks and the Ca2+ leak was 
calculated from spark volume, scan time and cell width.  
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3.2.8.1.4 Calibration of Fluo-4 
For calibration of Fluo-4 Fmax was measured by exposing the cells to 10 μM ionomycin 
in presence of 10 mM MnCl2 to saturate fluorescence (Yao et al., 1997). The cells were 
rinsed 10 min with Tyrode’s solution with Ca2+ and fluorescence was measured by line-
scan. Tyrode’s solution was then changed three times with calibration solution and 
fluorescence was measured every minute for a period of about 15 min. Fmax was then 
calculated as Fmax= 5xFMn and Fmin was calculated as Fmin=1/40 Fmax. [Ca]i was 
calculated using a Kd value of 864 nm (Merrit et al., 1990) and [Ca]i was calculated as 
[Ca]i = Kd x (F-Fmin)/(Fmax-F) (Grynkiewicz et al., 1985). 
3.2.8.2 Ca2+ imaging in skeletal muscle fibers 
3.2.8.2.1 Isolation of single skeletal muscle fibers  
Isolation of single skeletal muscle fibers was modified from Capote et al., 2005. FDB 
muscles were isolated from hind limps of dysferlin-null and wild-type mice after 
isoflurane anesthesia and following cervical dislocation and were then incubated in 
collagenase solution for 50 min at 37°C for enzymatic dissociation of muscle fibers. 
Muscle fibers were then striped of from tendons mechanically and were dissociated 
mechanically by pipetting up and down. Single skeletal muscle fibers were seed on 
laminin coated glass chambers and were incubated 30 min at room temperature until 
fibers were settled. Fibers were then incubated for 15 min in Fura-2 solution (10 μM). 
For caffeine-experiments Fura-2 solution contained 20 μM N-benzyl-p-toluene 
sulphonamide (BTS). For spark measurements fibers were incubated for 7 min in Fluo-
4 solution (10 µM). 
3.2.8.2.2 Detection of intracellular Ca2+ transients  
Detection of intracellular Ca2+ transients was done by epifluorescence microscopy with 
the same set up as in section 3.2.8.1.2 and measurements were performed at room 
temperature. The chamber was mounted on the microscope and was provided with a 
constant flow of 80 ml/h of Ringer’s solution with Ca2+. The chamber was rinsed at least 
10 min to remove excess dye and to allow cleavage of AM groups from the dye. The 
cells were incubated for another 10 min at a stimulation of 0.5 Hz to achieve a steady-
state. The ratiometric Ca2+ indicator dye Fura-2 AM was excited at 340 and 380 nm 
and emitted fluorescence at 510 nm was detected using a photomultipier. Ratiometric 
dyes change their excitation or emission spectrum according to the free Ca2+ 
concentration in the cytoplasm. Therefore, the ratio of the emission after excitation at 
340 respectively 380 nm directly correlates with the amount of intracellular Ca2+ after 
subtraction of the background fluorescence. Ca2+ transients were measured at 0.5, 1, 2 
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and 4 Hz. For measurement of SR Ca2+ content the cells were incubated for 4 min with 
Ringer’s solution without Ca2+ containing 20 μM BTS to inhibit contraction of muscle 
fibers (Pinniger et al., 2005) and SR Ca2+ release was evoked by addition of 30 mM 
caffeine solution containing 20 μM BTS. 
To measure the influence of mechanical stress on muscle fibers, wild-type and 
dysferlin knock-out mice were subjected to treadmill running. The mice were 
familiarized with the treadmill on 3 consecutive days for 15 min per day at a speed of 
15 m per min and a 0 % incline and were then subjected to running until exhaustion for 
90 min at a speed of 15 to 20 m per min (Wang et al., 2005). The control group 
continued to run for 15 min per day. Immediately after the last run the mice were killed 
and FDB muscles were isolated and Ca2+ transients were measured as described 
above. Analysis of Ca2+ transients was done with IONWizard Analyze Version 5.0 (ION 
OPTIX). 
3.2.8.2.3 Detection of Ca2+ sparks 
Measurement of Ca2+ sparks in FDB fibers was done like explained in section 3.2.8.1.3 
using the Ca2+ indicator Fluo-4. Compared to cardiomyocytes, in skeletal muscle fibers 
no Ca2+ sparks can be detected in healthy wild-type muscle. Therefore, Ca2+ sparks 
were measured after induction of osmotic shock (Wang et al., 2005). Cells were 
perfused with Ringer’s solution containing Ca2+ for 10 min and then the cells were 
shocked by perfusion with hypotonic solution for 100 s and Ca2+ sparks were measured 
for 15 min. 
3.2.9 Running wheel experiment 
The running wheel experiment was done in collaboration with David Liebetanz (UMG, 
Deptartment of Clinical Neurophysiology). Wild-type and dysferlin-null mice were 
housed individually and cages were mounted with a conventional running wheel at the 
age of 4, 12, 20, 40, 75 and 90 weeks over a period of three weeks. The running wheel 
was connected to a computer and daily voluntary running activity was monitored. One 
revolution corresponds to a running distance of 0.38 m. A rotation sensor with a 
resolution of 16/turn was connected to the wheel axis. Wheel activity was recorded 
using LabVIEW™-based custom software (National Instruments Corp.). In the first 
running period the mice reached the maximum running performance at day 12 and in 
the following running periods at day 8. Average daily distance (m) and average daily 
running velocity (m/s) was calculated from all values above a threshold of 40 % of the 
mean running distance started from day 12 or day 8 respectively. 
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3.2.10 Statistics 
Statistical analysis was done with Excel or GraphPad Prism 4 by student’s t-test or two-
way ANOVA for repeated measurements. P-values less than 0.05 were considered 
statistically significant. 
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4. Results  
4.1 Heterologous expression of dysferlin induces tubulation in non-muscle cells 
Previous unpublished work of my group demonstrated that heterologous expression of 
dysferlin in non-muscle cells lead to induction of tubular structures. These were shown 
to be newly induced membrane structures as cholesterol extraction by methyl-β-
cyclodextrin treatment resulted in depletion of the tubular structures. Dysferlin and its 
human homologues myoferlin and otoferlin belong to the family of ferlins and therefore 
have a very similar domain structure that may suggest a similar protein function. This 
lead to the question whether all ferlins are able to induce membrane structures after 
heterologous expression. To compare expression of the three ferlins, they were 
expressed as green fluorescent protein (GFP) or human influenza hemagglutinin (HA) 
fusion proteins in Cos 7 cells. As indicated in figure 4.1 expression of dysferlin in non-
muscle cells lead to induction of tubular structures which were not seen in cells 
transfected with the dysferlin homologues otoferlin or myoferlin. The network-like 
structure of myoferlin and otoferlin suggested ER localization of these two proteins 
which was corroborated by coimmunofluorescence staining of the ER with protein 
disulfide isomerase (PDI) (figure 4.1). In contrast, dysferlin-induced tubular structures 
did not show localization at the ER as indicated in figure 4.1. These results indicate that 
induction of membrane tubules in non-muscle cells is specific for dysferlin. 
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Figure 4.1: In contrast to its homologues oto- and myoferlin, dysferlin induces tubular 
structures after heterologous expression in Cos 7 cells. a) Cos 7 cells were transfected with 
GFP-dysferlin, GFP-otoferlin or myoferlin-HA (immunolabelled with anti-HA antibody) and 
analyzed 48 h after transient transfection. b) Transfected cells were co labeled with anti-PDI 
antibody as marker for the ER. Cells were analyzed by fluorescence microscopy, and z-stack 
images were deconvoluted. Scale bar: 10 μm. 
4.2 Dysferlin-induced tubules do not colocalize with any organelle of the cell 
To further analyze the tubular structures induced by dysferlin expression in Cos 7 cells, 
dysferlin-transfected cells were colabeled with several markers for cell organelles. As 
indicated in figure 4.2a, tubules induced by dysferlin did not colocalize with lamp1, 
Golgi protein 58K, PEX14 or Rab7. Therefore, the tubules were not localized to 
lysosomes, Golgi apparatus, late endosomes or peroxisomes which emphasizes the 
hypothesis that these tubules are a newly induced membrane compartment. In 
previous unpublished results from my group it was demonstrated that the tubules 
additionally did not colocalize with mitochondria and microtubules. Nevertheless, 
dysferlin-induced tubules are associated with the microtubule system as they were 
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disrupted by nocodazole-treatment, an agent interfering with microtubule 
polymerization (AG Thoms/Klinge, unpublished).  
 
 
Figure 4.2a: Dysferlin-induced tubules do not colocalize with organelle markers for 
lysosomes, Golgi-apparatus, peroxisomes and endosomes. Cos 7 cells were transfected 
with GFP-dysferlin or dysferlin-myc respectively (immunolaneled with anti-myc antibody) and 
costained with anti-lamp1 (lysosome-marker), anti-Golgi 58K (Golgi-marker) and anti-PEX14 
(peroxisome marker) or cotransfected with GFP-Rab7 (endosome marker). Cells were analyzed 
by fluorescence microscopy, and z-stack images were deconvoluted. Scale bar: 10 μm. 
 
Additionally, dysferlin-induced tubular structures did not colocalize with the actin 
cytoskeleton of the cell as shown by costaining of GFP-dysferlin-transfected cells with 
phalloidin (figure 4.2b). Furthermore, induction of tubules by dysferlin was not inhibited 
by cytochalasin D (cyto D), an agent depolimerizing the actin microfilaments, but cyto D 
seemed to stabilize the tubules as these structures showed a more pronounced 
appearance after treatment with cyto D (figure 4.2b). These results further confirm that 
dysferlin-induced tubules are newly induced membranous structures as they did not 
colocalize with any cellular organelle, the microtubule system or the cytoskeleton. 
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Figure 4.2b: Cytochalasin D stabilizes dysferin-induced tubules. Cos 7 cells were 
transfected with GFP-dysferlin, stained with phallioidin to visualize the actin cytoskeleton and 
were vehicle or cyto D treated afterwards. Dysferlin-induced tubules did not colocalize with the 
actin cytoskeleton but appear more pronounced after cyto D treatment. Cells were analyzed by 
confocal microscopy. Scale bar: 10 μm. 
4.3 Dysferlin-induced tubules are PIP2 and PIP3 containing membranes 
Extraction of cholesterol by methyl-β-cyclodextrin treatment lead to disruption of the 
tubular structures that were induced by heterologous dysferlin expression. 
Furthermore, the tubules did not colocalize with any cellular organelle, the microtubule 
system or with the actin cytoskeleton. Therefore, we concluded that these structures 
are tubular membranes induced by dysferlin expression in non-muscle cells. We further 
analyzed the dysferlin-induced tubular membranes in terms of its phospholipid 
composition. As it is known that dysferlin is located at the T-tubule system in skeletal 
muscle and that dysferlin is involved in formation of the T-tubule system the tubular 
structures were analyzed with regard to PIP2 and phosphatidiylinositol (3,4,5)-
trisphosphate (PIP3) composition, lipids that are found in T-tubule membranes (Milting 
et al., 1994). Pleckstrin homology domains (PH domains) have high affinity to 
phospholipids and are therefore often used to detect phospholipids. Recombinant PH 
domains of the signaling proteins Akt or PLCδ1 respectively were used as sensors for 
PIP3 and PIP2 and were coexpressed as GFP-fusion proteins with MYC-tagged 
dysferlin (done by Sven Thoms and Lars Klinge, figure 4.3.a). Dysferlin-induced 
membrane tubules indeed showed colocalization with both phospholipid sensors as 
indicated in figure 4.3a. This further substantiated that dysferlin-induced tubules are 
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membrane systems containing at least PIP2 and PIP3. To further analyze dysferlin with 
regard to PIP2, dysferlin was cotransfected with the PI(4)P5-kinase (PIP2 kinase) and 
the PIP2 phospatase synaptojanin 1. PIP2 kinase is a type I kinase that synthesizes 
PIP2 from PI4P. Expression of PIP2 kinase in Cos 7 cells leads to formation of PIP2-
containing vacuolar structures. As shown in figure 4.3.b, coexpression of the 
PIP2 kinase together with dysferlin lead to recruitment of dysferlin to the PIP2-
containing vacuolar structures indicating, that dysferlin bound PIP2 and was recruited 
to PIP2-containing membranes. PIP2 phospatase synaptojanin 1 dephosphorylates 
PIP2 thereby destructing PIP2 to PI4P. Interestingly, coexpression of dysferlin with the 
PIP2 phosphatase lead to partial colocalization of dysferlin and synaptojanin 1, and the 
dysferlin-induced tubular structures were disrupted (figure 4.3c). When truncated 
dysferlin constructs or pathogenic mutants were coexpressed with the PIP2 kinase no 
colocalization of the constructs with the kinase-induced vacuolar structures was 
detected (figure 4.3b). Additionally, no colocalization of the truncated or mutant 
dysferlin constructs with PIP2 phosphatase was detected (figure 4.3c). In conclusion, 
dysferlin was recruited to PIP2 kinase-induced vacuoles and this phenomenon required 
the full-length dysferlin protein. Furthermore, no tubule induction of the full-length 




Figure 4.3a: Dysferlin-induced tubules contain PIP2 and PIP3. Cos 7 cells were 
cotransfected with dysferlin-myc (immunolanelled with anti-MYC antibody) and GFP-PH-PLC 
(PIP2-sensor) or YFP-PH-Akt (PIP3-sensor) (done by Sven Thoms and Lars Klinge). Tubules 
induced by dysferlin colocalize with both lipid sensors. Cells were analyzed by fluorescence 
microscopy and z-stacks were deconvoluted. Scale bar: 10 μm. 
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Figure 4.3b: Only the full-length dysferlin is recruited to PIP2-containing vacuolar 
structures induced by PIP2 kinase. Cos 7 cell were cotransfect with GFP-tagged full-length, 
truncated or mutant constructs of dysferlin and the RFP-tagged PIP2 kinase. The full-length 
dysferlin did colocalize with the PIP2 kinase at vacuolar structures which was not detected with 
any of the truncated or mutant constructs of dysferlin. Cells were analyzed by fluorescence 
microscopy and z-stacks were deconvoluted. Scale bar: 10 μm. 
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Figure 4.3c: Dysferlin colocalizes with synaptojanin 1 but does not induce tubular 
structures in presence of synaptojanin 1. Cos 7 cells were transfected with GFP-tagged full 
length dysferlin, truncated or mutant constructs of dysferlin and RFP-synatojanin 1. The full-
length dysferlin colocalized with synaptojanin 1 but did not induce tubular structures in presence 
of synaptojanin 1. The truncated and mutant dysferlin constructs did not colocalize with 
synaptojanin 1. Cells were analyzed by fluorescence microscopy and z-stacks were 
deconvoluted. Scale bar: 10 μm. 
4.4 Induction of tubular membranes requires the full-length dysferlin protein 
The dysferlin protein has a molecular mass of about 230 kDa and contains two ferlin 
domains, seven C2 domains, and a transmembrane domain (TM). In order to learn 
more about the function of the dysferlin protein, it was necessary to identify functional 
domains of the protein. Four truncated constructs were generated and expressed in 
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Cos 7 cells (see figure 4.4b). Among them was minidyferlin which was found in a 
patient with a moderate and late onset dysferlinopathy consisting of the last two C2 
domains and a truncated N-terminal part of the protein that resulted from a frame shift 
mutation and a cryptic startcodon downstream of the natural ATG (Krahn et al. 2010). 
A second minidysferlin, called minidysferlin 3, was tested, which consisted again of the 
last two C2 domains and the C2A domain (Azakir et al. 2012). This minidysferlin 3 was 
claimed to have the same membrane repair capability like the full-length dysferlin 
protein (Azakir et al. 2012). Two further truncated dysferlin constructs were cloned 
including the last two C2 domains with (C2FGTM) and without the TM domain (C2FG). 
These constructs were tested for tubule induction in Cos 7 cells and the results in 
figure 4.4a indicate that none of the truncated dysferlin versions was able to induce 
tubular membrane structures like the full-length protein. Instead, all but the construct 
lacking the TM domain showed a network-like expression pattern which colocalized 
with the ER marker PDI (not shown). The construct lacking the TM domain was 




Figure 4.4a: The full-length dysferlin construct is needed for tubule induction. Cos 7 cells 
were transfected with GFP-tagged wild-type or truncated dysferlin constructs. None of the 
truncated constructs was able to induce tubulation like the full-length dysferlin. Cells were 
analyzed by fluorescence microscopy, and z-stack images were deconvoluted. Scale bar: 
10 μm. 
Results  54 
The truncated constructs were additionally expressed in C2C12 cells, a murine 
myoblast cell line, in order to examine the localization of the proteins. Dysferlin 
localized to the T-tubule system in C2C12 cells (Klinge et al., 2007). When the dysferlin 
full-length protein was expressed in these cells it showed T-tubule localization as it was 
seen previously (Klinge et al., 2007, figure 4.4b). In contrast, truncated dysferlin 
constructs did show a punctate expression pattern not suggesting localization at the 
intracellular network previously identified as T-tubule system (Klinge et al., 2007). With 
the minidysferlin construct we already analyzed a mutant version of dysferlin that 
derived from a patient. As most of the disease-causing variants are point mutations 
(Krahn et al., 2009) four pathogenic mutants of dysferlin were tested with regard to 
their tubule formation capacity. Three pathogenic mutants contain mutations in one of 
the C2 domains (mutation pG2999W in C2B, mutation pV398X in C2C or mutation 
pL1341P in C2E) and none of these mutants induced tubule formation in Cos 7 cells 
(experiment done by Sven Thoms and Lars Klinge, not shown) and none of these 
mutants did show localization at tubular structures in C2C12 cells (figure 4.4b). One 
mutant containing the point mutation between the C2D and C2E domains (mutation 
pR1333L) did induce tubular structures in about 20 % of Cos 7 cells. Furthermore, this 
mutant also partially showed a tubular expression pattern in C2C12 cells suggesting 
partial T-tubule localization. This indicates that pathogenic mutants of dysferlin were 
not able to induce or showed an impaired tubulation in Cos 7 cells and probably did not 
localize to the T-tubule system in C2C12 cells.  
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Figure 4.4b: In contrast to full-length dysferlin, most mutant and truncated dysferlins do 
not show tubular expression patterns in C2C12 cells. a) Domain diagram of dysferlin 
constructs used for transfection in Cos 7 and C2C12 cells. b) C2C12 cells were transfected with 
GFP-tagged dysferlin full-length construct, pathogenic mutants of dysferlin or truncated dysferlin 
constructs and analyzed by confocal microscopy. Only the full-length dysferlin localized to 
tubular network structures previously identified as the T-tubule system in C2C12 cells. Scale 
bar: 10 µm.  
4.5 Dysferlin-induced tubules are continuous with the plasma membrane 
It was already shown that dysferlin induced tubules in Cos 7 cells are newly build 
membrane structures that contain high amounts of the phospholipid PIP2 which is also 
found in membranes of the T-tubule system. The T-tubule system partly develops from 
invaginations of the plasma membrane. Therefore we analyzed whether dysferlin-
induced membranes in Cos 7 cells are continuous with the plasma membrane and 
possibly develop by invagination from the plasma membrane. FM4-64 is a fluorescent 
lipophilic dye that is often used to stain the plasma membrane of cells. GFP-dysferlin 
transfected Cos 7 and HeLa cells were costained with the membrane dye FM4-64. 
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Interestingly membrane tubules showed colabeling with the membrane dye in Hela 
(figure 4.5) and Cos 7 cells (not shown). After cyto D treatment the dysferlin-induced 
tubules appeared more pronounced as detected before and show colocalization with 




Figure 4.5: Dysferlin-induced tubules are continuous with the plasma membrane. Hela (a) 
or Cos 7 (b) cells were transfected with GFP-dysferlin, vehicle or cytochalasin D treated and 
costained with the plasma membrane dye FM4-64. Dysferlin-induced tubules colocalize with 
FM4-64 staining in vehicle and cyto D treated cells. Cells were analyzed by confocal microscopy 
(a) or fluorescence microscopy and deconvoluted afterwards (b). Scale bar: 10 μm. 
4.6 Full-length dysferlin binds to phospholipids in vitro 
The previous experiments demonstrated that dysferlin colocalized with the 
phospholipids PIP2 and PIP3 and that dysferlin is recruited to PIP2-containing 
structures. This indicates that dysferlin binds to phospholipids, and especially to PIP2. 
Therrien et al. showed in vitro that the C2A domain of dysferlin binds to phospholipids 
in a Ca2+-dependent manner, but so far in vitro lipid binding studies with the full-length 
dysferlin protein have not been published. To test the lipid binding ability of dysferlin, 
full-length dysferlin protein, minidysferlin 3 and a pathogenic mutant of dysferlin 
(mutant pV67D in C2A) were expressed as His6-tagged proteins by an E.coli 
expression system. Commercially available PIP strips blotted with several 
phospholipids found in mammalian membranes were used to detect dysferlin binding. 
Bin1, a BAR-domain protein localizing to the T-tubule system in skeletal muscle (Butler 
et al. 1997), is known to bind phospholipids, especially PIP2 and was therefore used as 
positive control. The results corroborated the expected binding of Bin1 to PIP2 which 
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furthermore binds to phosphatidylinositol (3)-phosphate (PI3P) (figure 4.6a). Like Bin1, 
the dysferlin full-length protein and minidysferlin 3 showed binding to PIP2 and PI3P. 
Interestingly, the dysferlin mutant V67D which contains a mutation in the C2A domain 
did only show binding affinity to PI3P but not PIP2. Bin1 and full-length dysferlin did 
also bind to phosphatidic acid. The results show that the full-length dysferlin bound to 




Figure 4.6a: Full-length dysferlin binds to PIP2 and the C2A domain is necessary for this 
binding. Bin1, full-length dysferlin, minidysferlin 3 and a dysferlin mutant (V67D) were 
expressed in E.coli expression systems as His6-tagged (full-length dysferlin and mutant V67D) 
or GST-fusion proteins (Bin1 and minidysferlin 3). PIP strips (Echelon) were incubated with 
protein lysates and the proteins were detected by primary antibodies against dysferlin, Bin1, or 
GST, secondary HRP-coupled antibodies and chemiluminescence. 
 
PIP strips are usually used as a first screening of protein lipid binding. To further 
support observations by the PIP-strip experiments, liposome flotation experiments were 
performed. Liposomes were prepared from Folch fraction lipids containing additional 
5 % PIP2 or PI3P or Folch fraction lipids only and were incubated in presence of Ca2+ 
with dysferlin or Bin1 which was used as positive control. Sucrose gradient 
centrifugation was carried out and fractions were analyzed by Western blotting to 
detect flotation of proteins. Membranes were recovered from the top fraction and 
unbound protein remained in the lower fractions. As shown in figure 4.6b Bin1 was 
detected in the top fraction in presence of Folch fraction liposomes as well as Folch 
fraction liposomes with 5 % added PIP2. In absence of liposomes, no Bin1 protein was 
detected in the top fraction. Dysferlin protein was detected in the top fraction only in 
presence of Folch fraction lipids containing 5 % PIP2. In absence of liposomes or 
liposomes made of Folch fraction lipids containing 5 % PI3P or Folch fraction lipids 
only, no flotation of protein was detected. These results confirm the binding affinity of 
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the dysferlin full-length protein to the phospholipid PIP2. In contrast, no binding of 




Figure 4.6b: Dysferlin is able to bind to PIP2. Liposomes were made of Folch fraction lipids 
containing 5 % PIP2 or PI3P or Folch lipids only and extruded through a 100 nm filter. 
Liposomes or buffer (as negative control) were incubated with dysferlin or Bin1, overlayed with 
a sucrose gradient and ultracentrifugation was carried out followed by fractionation and Western 
blot. T = top fraction, B = bottom fraction. 
4.7 Dysferlin tubulates membranes in vitro 
Dysferlin is able to induce a tubular membrane network continuous with the plasma 
membrane when expressed in non-muscle cells. These membranes contain high 
amounts of PIP2, a phospholipid found in the T-tubule system of skeletal muscle. 
Furthermore, it was demonstrated that dysferlin was able to bind phospholipids in vitro. 
These findings suggest that dysferlin is able to mediate membrane tubulation. To 
determine the ability of dysferlin to tubulate or deform biological membranes in vitro, a 
liposome tubulation assay with recombinant dysferlin full-length protein was performed. 
As Bin1 is able to induce tubulation of liposomes (Lee et. el., 2002) this protein was 
used as positive control. Liposomes made of Folch fraction 1 lipids were incubated with 
the recombinant proteins in presence of Ca2+ and analyzed by electron microscopy. As 
indicated in figure 4.7a, Bin1 as expected induced tubulation of liposomes. 
Interestingly, also the dysferlin full-length protein did induce liposome tubulation in this 
cell-free system. The pathogenic C2A mutant of dysferlin and minidysferlin 3 did not 
induce tubulation. When 5 % PIP2 was added to Folch fraction lipids, tubulation of 
liposomes by dysferlin was increased and tubulation appeared more pronounced 
compared to tubulation of Folch liposomes. These results gave evidence that dysferlin 
exhibits a powerful membrane deformation capacity and that presence of PIP2 lipids in 
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biological membranes increases tubulation properties of dysferlin. Minidysferlin 3 failed 
to tubulate membranes in vitro which indicates that the full-length protein is necessary 
for tubulation. Further, the C2A mutant of dysferlin also failed to induce tubulation 
therefore, the C2A domain is not only necessary for PIP2 binding but is also required 
for liposome tubulation. 
The important role of the C2A domain was further confirmed by a liposome binding 
experiment using the single C2 domains of dysferlin. The recombinant C2 domain 
proteins of dysferlin were incubated with liposomes made from Folch fraction lipids 
containing 5 % NBD-PE (7-nitro-2-1,3-benzoxadiazole-4-yl phosphatidylethanolamine) 
in presence of Ca2+ and were analyzed by fluorescence microscopy (figure 4.7b). The 
results demonstrate that the C2A domain of dysferlin induced aggregation of liposomes 
which was not detected with the other C2 domains. This further indicates the crucial 




Figure 4.7a: Dysferlin induces tubulation of membranes in vitro. Dysferlin full-length 
protein, dysferlin mutant V67D, minidysferlin 3 and Bin1 were expressed in E.coli expression 
systems, incubated with liposomes made from Folch fraction 1 lipids and extruded through a 
100 nm filter afterwards, absorbed onto formvar coated copper grids, stained with 2 % PTA and 
analyzed by EM. Bin1 and dysferlin were able to induce tubulation of liposomes in presence of 
Ca
2+
 whereas the minidysferlin 3 and the C2A mutant of dysferlin were not. Tubulation efficiency 
of dysferlin increased when 5 % PIP2 were present in liposomes. Scale bar: 0.2μm. 
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Figure 4.7b: The C2A domain of dysferlin aggregates liposomes in vitro. The seven C2 
domains were expressed as GST-tagged proteins in e.coli expression systems, refolded after 
urea denaturation and incubated with liposomes prepared from Folch fraction lipids and 
5 % NBD-PE and Ca
2+
 and analyzed by fluorescence microscopy. Only the C2A domain lead to 
aggregation of liposomes in presence of Ca
2+
. Scale bar 20 μm. 
4.8 Dysferlin is localized at the T-tubule system in cardiomyozytes 
In heart muscle dysferlin protein is expressed twice as high as in skeletal muscle 
(Anderson et al., 1999). Furthermore, it was shown that dysferlin knock-out mice 
develop a cardiomyopathy after stress exercise (Han et al., 2007) and in some patients 
with dysferlin-deficiency a cardiomyopathy was also described (Kuru et al., 2004; 
Wenzel et al., 2007; Guglieri et al., 2008) although this appears not a regular feature of 
dysferlin-deficiency. These are indications of a possible physiological function of 
dysferlin not only in skeletal but also in heart muscle which made further analysis of 
dysferlin in cardiomyocytes necessary. In order to analyze the localization of dysferlin 
coimmunofluorescence labeling with the DHPR as a T-tubule marker was performed. 
As shown in figure 4.8, dysferlin localized to the T-tubule system also in 
cardiomyocytes. 




Figure 4.8: Dysferlin localizes to the T-tubule system in dysferlin-deficient 
cardiomyocytes. Cardiomyocytes were isolated from hearts of wild-type mice (20 weeks old) 
and stained with antibodies against dysferlin and DHPR. Cells were analyzed by fluorescence 
microscopy and z-stacks were deconvoluted. Scale bar: 10 μm. 
4.9 Dysferlin-deficient cardiomyocytes show an abnormal T-tubule system 
It was previously shown that dysferlin localizes to the T-tubule system in skeletal 
muscle and that the T-tubule system in dysferlin-deficient skeletal muscle is of 
abnormal morphology (Klinge et al., 2010). As dysferlin also localizes to the T-tubule 
system in heart muscle, dysferlin-deficiency may have an influence on the morphology 
of the T-tubule system in cardiomyocytes. Di-8-butyl-aminonaphthyl-ethylene-
pyridinium-proply-sulfonate (Di8ANEPPS) is a membrane dye that can be applied to 
detect the T-tubule system in living cardiomyocytes (Nishimura et al., 2006). Staining of 
isolated wild-type cardiomyocytes showed the regular staining pattern of the T-tubule 
system with mainly transversal orientation (figure 4.9). In contrast, staining of dysferlin 
knock-out cardiomyocytes revealed an irregular, dilated and predominantly longitudinal 
orientated T-tubule system (figure 4.9, done by Viacheslav Nikolaev). This indicates 
that dysferlin is crucial not only for maintenance of normal T-tubule structure in skeletal 
muscle, but also of heart muscle. 
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Figure 4.9: The T-tubule system in dysferlin-deficient cardiomyocytes shows an 
abnormal configuration. Cardiomyocytes from young (19 weeks) and aged (50 weeks) 
dysferlin-null and wild-type mice were isolated, stained with the membrane dye Di8ANEPPS 
and analyzed by confocal microscopy (done by Viacheslav Nikolaev). Scale bar 10 μm. 
4.10 Dysferlin is upregulated after myocardial infarction 
We have now demonstrated that dysferlin localizes to the T-tubule system in 
cardiomyocytes and that in the T-tubule system of heart muscle is irregularly 
configured when dysferlin is absent. Furthermore, it was shown in previous 
experiments that dysferlin binds to phospholipids and is able to mediate membrane 
tubulation. This lead to the hypothesis, that dysferlin may also play a role in the 
process of T-tubule biogenesis in heart muscle and furthermore in T-tubule 
remodelling, a process that is implicated in hearts after myocardial infarction (MI). 
Therefore, a dysferlin Western blot was carried out with samples from rat heart 
homogenates after MI and sham-treated hearts (provided by Viacheslav Nikolaev). As 
indicated in figure 4.10, protein levels of dysferlin were significantly upregulated in rat 
hearts after MI when compared to sham-treated hearts. This indicates a role of 
dysferlin in the process of T-tubule remodelling after MI.  
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Figure 4.10: Dysferlin is upregulated after myocardial infarction. Myocardial infarction (MI) 
was induced in rat hearts by ligation of the left coronary artery (samples provided by Viacheslav 
Nicolaev). Homogenates of rat hearts after induction of MI or sham treatment were separated 
by SDS gel electrophoresis, blotted onto nitrocellulose membranes, incubated with a dysferlin 
antibody and detected by chemiluminescence (b). Protein levels were determined by 
densitometry using Image J analysis software and were normalized to tubulin to ensure equal 
protein loading. Protein levels of KO hearts were then normalized to WT hearts (a). *p<0.05, 
N = 4 per group. 
4.11 Analysis of Ca2+ release and shortening in cardiomyocytes 
4.11.1 Ca2+ release and shortening are not altered in dysferlin-deficient 
cardiomyocytes 
It was shown that dysferlin localizes to the T-tubule system in cardiomyocytes and that 
dysferlin-deficiency leads to an irregular conformation of the T-tubule system. The T-
tubule system is required for propagation of the action potential into the interior of the 
cardiomyocyte where the process of excitation-contraction coupling (EC-coupling) is 
initiated. To investigate possible functional consequences of an abnormal T-tubule 
morphology in dysferlin-deficiency on the process of EC-coupling Ca2+ measurements 
in isolated cardiomyocytes were carried out in cooperation with the lab of Lars Maier 
(Department of Cardiology, UMG). Single cardiomyocytes were isolated from wild-type 
and dysferlin-deficient mice (50 weeks of age) and loaded with the Ca2+-sensitive dye 
Fluo-4. Cells were electrically stimulated at 0.5 to 4 Hz and Ca2+ release and fractional 
shortening of the cardiomyocytes was detected by epifluorescence microscopy. 
Increasing the stimulation frequency modifies the amplitude and contraction kinetics as 
well as relaxation kinetics which depend on sarcoplasmatic reticulum (SR) Ca2+ load, 
SR Ca2+ uptake and ryanodine receptor 2 (RYR2) inactivation. As shown in 
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figure 4.11.1, the Ca2+ transient amplitudes of wild-type and knock-out cardiomyocytes 
showed a negative force-frequency relationship. Fractional shortening of both groups 
decreased from 0.5 to 1 Hz and increased again with higher frequency. The results 
showed no significant differences in Ca2+ release and fractional shortening of knock-out 
and wild-type cardiomyocytes. Additional parameters like relaxation time and time to 
peak of both, the Ca2+ transient amplitudes and the fractional shortening of the cells did 
not show significant differences between knock-out and control group. The relaxation 
time is the time needed to transport the released Ca2+ back into the SR (by SR Ca2+-
ATPase (SERCA)) and out of the cell (by Na+/Ca2+-exchanger (NCX) or sarcolemmal 
Ca2+ pump). The parameter 50 % relaxation time describes the time that is needed to 
decrease the Ca2+ transient and the contraction to 50 % of its peak value. As in mouse 
cardiomyocytes 92 % of Ca2+ is transported back into the SR (Maier et al., 2000) and 
only 7 % are transported out of the cell by NCX and 1 % by the sarcolemmal Ca2+ 
pump, the relaxation time depends mainly on SERCA and therefore can be considered 
as an indicator for SERCA function. At higher heart-rates a process called frequency-
dependent acceleration of relaxation (FDAR) leads to rapid refilling of the SR Ca2+ 
store (Maier and Bers, 2002). As indicated in figure 4.11.1, FDAR occurred in all cells 
for both, Ca2+ transient amplitudes and shortening. The time to peak is the time from 
electrical stimulation of the cell until the peak of Ca2+ release, respectively contraction, 
is reached witch includes activation of dihydropyridine receptor (DHPR), coupled gating 
of DHPR and RyR and Ca2+ release of RyR. The time to peak is therefore a measure 
for the contractility process of the cell. Both, SERCA function and contractility were not 
altered in dysferlin-deficient cardiomyocytes. These results point out that under normal 
physiological conditions Ca2+ homeostasis is not altered in dysferlin-deficient 
cardiomyocytes. 





 release and fractional shortening of dysferlin-deficient 
cardiomyocytes are not altered under normal conditions. Isolated cardiomyocytes were 
loaded with Fluo-4 and Ca
2+
 release and shortening were detected after stimulation with 0.5 to 
4 Hz. (a) Average Ca
2+
 transient amplitudes (left) and fractional shortening (right). (b) Average 
time to peak and 50 % relaxation time of Ca
2+
 transient amplitudes (c) Representative steady-
state (1 Hz) Ca
2+
 transient amplitudes and fractional shortening of WT and KO cardiomyocytes 
(d) Average time to peak and 50 % relaxation time of fractional shortening. Data presented as 
mean +/- SEM, N = 7 mice and ≥ 8 fibers. 
4.11.2 Isoprenaline treatment unmasks deficits of dysferlin-deficient 
cardiomyocytes 
Isoprenaline as a ß1 and ß2-receptor agonist has positive ionotropic effects on hearts 
(Schwinger et. al., 1993) by activating cAMP-dependent pathways which increase 
intracellular Ca2+ transients (Pieske et al., 1997). Therefore, isoprenaline is often used 
to induce a stress situation in cardiomyocytes. As indicated in figure 4.11.2, 
isoprenaline treatment lead to significantly increased Ca2+ release and significantly 
increased contraction in both, dysferlin-deficient and wild-type cardiomyocytes. 
Interestingly, the dysferlin-deficient cardiomyocytes showed significantly decreased 
Ca2+ release compared to wild-type cells after isoprenaline treatment indicating 
significant deficits of dysferlin-deficient cardiomyocytes after isoprenaline treatment. 
Furthermore, isoprenaline treatment significantly increased the time to peak and the 
relaxation time of Ca2+ release and shortening of the cells but no differences were 
observed between knock-out and wild-type cardiomyocytes. 





 release of dysferlin-deficient cardiomyocytes is significantly 
decreased after induction of stress by isoprenaline. Isolated cardiomyocytes were loaded 
with Fuo-4 and treated with the ß-receptor agonist isoprenaline (10
-7
M). a) Average Ca
2+
 
transient amplitudes (left) and fractional shortening (right) at 1 Hz. (b) Average time to peak and 
relaxation times of Ca
2+
 transient amplitudes at 1 Hz (c) Representative steady-state (1 Hz) 
Ca
2+
 transient amplitudes and fractional shortening of WT and KO cardiomyocytes (d) Average 
time to peak and relaxation times of fractional shortening at 1 Hz. Data presented as mean +/-
 SEM (*p<0.05 vs. WT, #p<0.05 vs.WT+ISO, †p<0.05 vs. KO), N = 7 mice and ≥ 24 fibers per 
group. 
4.11.3 Significantly decreased SR Ca2+ content in dysferlin-deficient 
cardiomyocytes 
Rapid application of caffeine leads to reversible opening of RyR channels thereby 
releasing all Ca2+ from the SR. This is a very efficient experimental method often used 
to determine the SR Ca2+ load of cardiomyocytes. The caffeine-induced Ca2+ transient 
can be directly used to calculate the Ca2+ content of the SR. The results shown in 
figure 4.11.3a indicate that the SR Ca2+ content of the dysferlin-deficient 
cardiomyocytes was significantly decreased compared to wild-type cells. The 
decreased SR Ca2+ content was already seen in the vehicle-treated cells and became 
even more obvious after isoprenaline treatment. In presence of caffeine, the Ca2+ ions 
that are transported back into the SR by SERCA are directly released again by the 
opened RyR channel. Therefore, the relaxation time of the caffeine-induced transient is 
an indicator for the NCX function. As shown in figure 4.11.3a the NCX function of the 
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dysferlin-deficient cardiomyocytes was significantly decreased. A further indicator of 
the Ca2+ content of the SR is the post-rest relation (Bers et al., 2001). The results 
indicate that Ca2+ release and shortening of vehicle-treated wild-type and dysferlin-
deficient cells after an unstimulated pause of 30 s was significantly increased 
compared to the steady-state Ca2+ release (figure 4.11.3b). No differences between 
knock-out and wild-type cells were detected. Isoprenaline treatment lead to a 
significantly decreased post-rest Ca2+ release of dysferlin-deficient cardiomyocytes 
compared to the wild-type Ca2+ release. This also indicates a decreased SR Ca2+ 
content in dysferlin-deficient cardiomyocytes. 
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Figure 4.11.3a: Significantly decreased SR Ca
2+
 content and increased NCX function in 
dysferlin-deficient cardiomyocytes. 10 mM caffeine was rapidly applied to isolated vehicle- or 
isoprenaline- (10
-7
 M) treated cardiomyocytes. a) Representative steady-state (1 Hz) and 
caffeine-induced Ca
2+
 transient amplitudes of vehicle- or isoprenaline-treated cells b) Average 
steady-state and caffeine-induced Ca
2+
 transient amplitudes of vehicle- and isoprenaline-treated 
cells (left) and average relaxation times of the caffeine-induced Ca
2+
 transients of vehicle- and 
isoprenaline-treated cells (right). Data presented as mean +/- SEM (*p<0.05 vs. WT, #p<0.05 
vs.WT+ISO, †p<0.05 vs. KO), N = 7 mice and ≥ 11 fibers per group. 
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Figure 4.11.3b: Isoprenaline-induced stress leads to significantly reduced post-rest Ca
2+
 
release in dysferlin-deficient cardiomyocytes. a) Representative steady-state and post-rest 
Ca
2+
 transients and fractional shortening of vehicle-treated wild-type and knock-out cells b) 
Average steady-state (1 Hz) and post-rest (30 s) Ca
2+
 transient amplitudes and fractional 
shortening of vehicle- and isoprenaline-treated cells. Data presented as mean +/- SEM (*p<0.05 
vs. WT, #p<0.05 vs.WT+ISO, †p<0.05 vs. KO), N = 7 mice and ≥ 17 fibers per group. 
4.12 Spark measurements revealed a significantly increased SR Ca2+ leak in 
dysferlin-deficient cardiomyocytes 
The previous experiments revealed a significantly decreased SR Ca2+ content and a 
significantly decreased post-rest Ca2+ release after isoprenaline treatment of dysferlin-
deficient cardiomyocytes. Both results lead to the hypothesis that the SR of dysferlin-
deficient cardiomyocytes loses Ca2+ probably during diastole, the resting period, of the 
cell. This hypothesis was further analyzed by spark-measurements. Ca2+ sparks are 
local events of Ca2+ release through the RyR2 channel which occur during EC-coupling 
but also during diastole of the cells. Frequency, duration, amplitude and width of the 
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single sparks contribute to the SR Ca2+ leak. Spark measurements were performed by 
confocal microscopy using Fluo-4 loaded single isolated cardiomyocytes. The results 
shown in figure 4.12a revealed a significantly increased diastolic SR Ca2+ leak in 
dysferlin-deficient cardiomyocytes. This was due to a significantly increased spark 
frequency of the knock-out cells. All other parameters were not altered compared to 
wild-type cardiomyocytes. Isoprenaline treatment increased the SR Ca2+ leak in wild-
type as well as in dyferlin-deficient cardiomyocytes compared to the vehicle-treated 
cells. Isoprenaline-treated dysferlin-deficient cardiomyocytes revealed a significantly 
increased spark width and duration, suggesting a prolonged opening of RyR2, but no 
alterated spark amplitude compared to the isoprenaline-treated wild-type cells. The 
significantly increased SR Ca2+ leak with prolonged opening of RYR2 especially after 
induction of stress suggested an increased probability of arrhythmias due to delayed 
afterdepolarizations in dysferlin-deficient heart muscle. A further indication for an 
increased probability of arrhythmias was the occurrence of nonstimulated events in 
electrically paced cardiomyocytes. These were detected during the measurement of 
Ca2+ transients and shortening by epifluorescece microscopy and these 
proarrythmogenic events occurred during steady-state stimulation and when 
stimulation was paused to measure the post-rest relation (figure 4.12b). The results in 
figure 4.12b indicate that proarrhythmogenic events occurred in both, wild-type and 
dysferlin-deficient cardiomyocytes, but were more frequent in dysferlin-deficient 
cardiomyocytes. Especially after treatment with isoprenaline nonstimulated events 
were significantly more frequent in dysferlin-deficient cells relative to wild-type cells. In 
dysferlin-deficient cardiomyocytes isoprenaline treatment lead to induction of sustained 
cellular tachycardia, which was not observed in wild-type cells or in vehicle-treated 
dysferlin-deficient cardiomyocytes. This indicates that dysferlin-deficient 
cardiomyocytes are prone to arrhythmia especially after induction of stress. 





 spark measurements reveale a significantly increased SR Ca
2+
 leak. 
Significantly increased spark frequency of dysferlin-deficient cardiomyocytes lead to a 
significantly increased diastolic Ca
2+
 leak. (a) Representative line scan images (∆F/F0, 
0.96 ms/line) of vehicle- and isoprenaline-treated KO and WT cardiomyocytes. (b) Average 
spark frequency, diastolic [Ca
2+
], diastolic SR Ca
2+
 leak and spatiotemporal properties of Ca
2+
 
sparks, such as amplitude, full duration at half maximum and spatial spread (full width at half 
maximum). Data presented as mean+/- SEM. *P<0.05 vs. WT, †P<0.05 vs. KO #P<0.05 vs. 
WT+ISO. Horizontal scale bar: 200ms, vertical scale bar: 10 µm, N ≥ 4 mice and ≥ 40 fibers per 
group.
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Figure 4.12b: Significantly increased proarrhythmogenic events in isoprenaline-treated 
dysferlin-deficient cardiomyocytes. a) Original traces of fractional shortening after vehicle or 
isoprenaline treatment (10
-7
 M) at 1 Hz showing spontaneous cellular arrhythmias (*). b) 
Average arrhythmia score per observation time. Data presented as mean +/- SEM. #P<0.05 vs. 
WT+ISO, vertical scale bars: 0.05 %, horizontal scale bars: 2 s. 
 
4.13 Biometric data 
Biometric data like age, heart weight and body weight were determined of mice that 
were used for Ca2+ measurements. Mice were 50 to 60 weeks old and dysferlin-
deficient mice had a significantly decreased body weight but did not show any 
differences in their heart weight/body weight ratio. Therefore, aged dysferlin-deficient 
mice did not show signs of overt cardiac hypertrophy (figure 4.13). 
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Figure 4.13: Dysferlin-deficient mice do not show signs of hypertrophy. Biometric data 
were determined from mice used for Ca
2+
-measurements. a) heart weight, b) body weight, c) 
heart weight/body weight ratio as indicator for hypertrophy, d) age. Data presented as mean +/-
 SEM, *p< 0.05 versus WT, N = 10 mice per group. 
 
4.14 Analysis of Ca2+ release in skeletal muscle fibers 
4.14.1 Increased Ca2+ release in dysferlin-deficient muscle fibers 
Dysferlin localizes to the T-tubule system (Klinge et al., 2008) and dysferlin-deficient 
skeletal muscle fibers of mice have a structurally irregular, longitudinally oriented and 
dilated T-tubule system. As the T-tubule system is a key player in the process of EC-
coupling it was necessary to further investigate functional consequences of the 
aberrant T-tubule system regarding the EC-coupling process also in skeletal muscle 
fibers. Ca2+ release in isolated single skeletal muscle fibers was measured by 
epifluorescence microscopy in cooperation with Lars Maier (Department of Cardiology, 
UMG). Single skeletal muscle fibers were isolated from flexor digitorm brevis (FDB) 
muscles from young (6-20 weeks) and aged (>50 weeks) wild-type and dysferlin knock-
out mice and loaded with the Ca2+ sensor Fura-2. Ca2+ transient amplitudes were 
measured at 0.5 to 4 Hz stimulation to analyze whether a force-frequency relationship 
like it was seen in cardiomyocytes exists in skeletal muscle fibers and if it shows any 
differences between wild-type and dysferlin-deficient cells. As shown in figure 4.14.1a, 
Ca2+ release was significantly increased in muscle fibers from young dysferlin-deficient 
mice. Ca2+ release was also increased in aged dysferlin-deficient mice but this increase 
was not statistically significant at the single frequencies. Baseline Ca2+ fluorescence as 
indicator for the resting Ca2+ concentration was not altered in knock-out compared to 
wild-type mice. 





 release of dysferlin-deficient skeletal muscle fibers is significantly 
increased. Single skeletal muscle fibers were loaded with Fura-2 and Ca
2+
 transient amplitudes 
(left) and baseline Ca
2+
 fluorescence (right) of skeletal muscle fibers from (a) 6-20 weeks old 
mice and (b) >50 weeks old mice were detected. Baseline Ca
2+
 fluorescence was not altered 
but Ca
2+
 release was significantly increased in young and aged mice. Data presented as mean 
+/-SEM, *p<0.05, N ≥ 3 mice and ≥ 36 fibers per group. 
 
As in cardiomyocytes the relaxation time in skeletal muscle fibers serves as indicator 
for SERCA function, as most of the Ca2+ is transported back into the SR by SERCA 
and only small parts of Ca2+ are transported out of the cell by NCX and the plasma 
membrane Ca2+ ATPase (PMCA). The time to peak can be considered as an indicator 
for the contractility of the cell as it involves processes like activation of DHPR, coupling 
of DHPR and RYR and Ca2+ release from the SR by RyR1. As indicated in 
figure 4.14.1b, both parameters, relaxation time and time to peak were not altered in 
skeletal muscle fibers from young dysferlin-deficient mice. In contrast, skeletal muscle 
fibers from aged dysferlin-deficient mice revealed significantly increased relaxation 
times and therefore a decreased SERCA function. Furthermore, also the time to peak 
was significantly increased, indicating a decreased contractility process in skeletal 
muscle fibers from aged dysferlin knock-out mice. These results revealed an altered 
Ca2+ homeostasis in dysferlin-deficient skeletal muscle. 
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Figure 4.14.1b: Relaxation time and time to peak are significantly increased in skeletal 
muscle fibers of aged dysferlin-deficient mice. Average relaxation time at 0.5 Hz (left) and 
time to peak (right) of Ca
2+
 transient amplitudes of skeletal muscle fibers from (a) young and (b) 
aged mice. Both parameters were not altered in young dysferlin-deficient mice but significantly 
decreased in aged dysferlin-deficient mice. Data presented as mean +/- SEM, *p<0.05, N ≥ 3 x 
mice and ≥ 36 fibers per group. 
 
4.14.2 Increased Ca2+ release is specific for dysferlin-deficient muscular 
dystrophy 
To analyze whether increased Ca2+ amplitudes are specific for dysferlin-deficient 
skeletal muscle fibers and are not secondary due to the dystrophic process, Ca2+ 
release was also measured in muscle fibers from dystrophin-deficient mdx mice. Mdx 
mice are a model for dystrophin-deficient muscular dystrophy and the best-studied 
muscular dystrophy mouse model. As indicated in figure 4.14.2, the dystrohin-deficient 
skeletal muscle fibers revealed significantly decreased Ca2+ release related to wild-type 
and dysferlin-deficient mice and furthermore showed a significantly prolonged 
relaxation time indicating a decreased SERCA function. Resting Ca2+ concentration 
was not significantly altered in mdx mice compared to wild-type and dysferlin-deficient 
mice. These results were consistent with previously published results that 
demonstrated decreased Ca2+ transient amplitudes and decreased SERCA function in 
mdx mice.  
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Figure 4.14.2: Increased Ca
2+
 release is specific for dysferlin-deficient skeletal muscle 
fibers and not due to the dystrophic muscle. (a) Average Ca
2+
 transient amplitudes, baseline 
fluorescence and 50 % relaxation time at 0.5 Hz stimulation of wild-type, dysferlin-deficient and 
mdx skeletal muscle fibers. (b) Representative steady-state Ca
2+
 transient amplitudes at 0.5 Hz 
stimulation. Data presented as mean +/- SEM, *p<0.05, N ≥ 3 mice and ≥ 40 fibers per group, 
vertical scale bar: 0.01 Ratio, horizontal scale bar: 0.05 s. 
 
4.14.3 Influence of mechanical stress on Ca2+ homeostasis skeletal muscle fibers 
To determine the influence of mechanical stress on Ca2+ release of young dysferlin-
deficient skeletal muscle mice were subjected to fatigue exercise treadmill running and 
Ca2+ release was measured directly after the last exercise session. The results 
revealed a significantly increased baseline Ca2+ fluorescence which indicated a 
significantly increased resting Ca2+ concentration after exercise in both, dysferlin-null 
and wild-type mice. Furthermore, no significant changes of Ca2+ release and time to 
peak between exercised and non-exercised muscle fibers of dysferlin-deficient and 
wild-type mice could be observed. The relaxation time of wild-type muscle fibers 
increased significantly after stress exercise but the relaxation time of knock-out muscle 
fibers was not altered after stress exercise. In summary, myofibers of wild-type mice 
showed an increased resting Ca2+ concentration and increased SERCA function after 
stress exercise compared to non-exercised muscle fibers and dysferlin-deficient 
muscle fibers only revealed an increased resting Ca2+ concentration without alteration 
of further parameters.  
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 release was 
measured in wild-type and knock-out muscle fibers after mild and fatiguing exercise treadmill 
running. Fatiguing exercise did not lead to significant changes of Ca
2+
 release in wild-type and 
knock-out mice related to Ca
2+
 release after mild exercise but resting Ca
2+
 was significantly 
increased in both groups after exercise. Average a) Ca
2+
 transient amplitudes, b) 50 % 
relaxation time, c) baseline fluorescence and d) time to peak at 0.5 Hz. Data presented as 
mean +/- SEM. *P<0.05 vs. WT, †P<0.05 vs. KO, #P<0.05 vs. WT + exercise, N ≥ 5 mice and 
≥ 41 fibers per group. 
 
4.14.4 SR Ca2+ content is not significantly altered in young dysferlin-deficient 
mice 
To determine whether the altered Ca2+ homeostasis of young dysferlin-deficient 
skeletal muscle fibers is due to an increased Ca2+ content of the SR, caffeine-induced 
Ca2+ release was measured. As in cardiomyocytes, rapid application of caffeine leads 
to opening of RyR1 receptors and therefore to release of all Ca2+ ions stored in the SR. 
As shown in figure 4.14.4, the SR Ca2+ content was not significantly altered in dysferlin-
deficient skeletal muscle fibers related to wild-type fibers. Furthermore, relaxation time 
of the caffeine-induced Ca2+ transients did not show significant differences compared to 
wild-type fibers. The relaxation time of the caffeine-induced Ca2+ transient is due to the 
transport of Ca2+ out of the cell. Ca2+ that is transported back into the SR, is 
immediately released again through the opened RyR, therefore the relaxation time is 
an indicator for PMCA and NCX function in skeletal muscle fibers. Caffeine-
experiments revealed no alteration in PMCA and NCX function in young dysferlin-
deficient muscle fibers. 
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Figure 4.14.4: No alteration of SR Ca
2+
 content and PMCA/NCX function in dysferlin-
deficient skeletal muscle fibers. 30 mM caffeine was rapidly applied to isolated skeletal 
muscle fibers. a) Average caffeine-induced Ca
2+
 transient amplitudes. b) Average relaxation 
times of the caffeine induced Ca
2+
 transients. Data presented as mean +/- SEM, N = 4 mice and 
≥ 17 fibers per group. 
 
4.14.5 Increased Ca2+ transients depend on external Ca2+ 
Young dysferlin-deficient mice reveal increased Ca2+ transient amplitudes but do not 
contain an increased SR Ca2+ content. Therefore we addressed the question whether 
the processes of excitation-coupled Ca2+ entry (ECCE) or store-operated Ca2+ entry 
(SOCE) are altered in these mice. To test this, Ca2+ depletion was carried out. Ca2+ 
transient amplitudes from wild-type and dysferlin-deficient skeletal muscle fibers were 
analyzed after changing perfusion of cells from medium containing Ca2+ to Ca2+-free 
medium. The results showed that Ca2+ transient amplitudes were significantly 
increased in dysferlin-deficient fibers from 0 to 4 min after changing to Ca2+-free 
medium, the time when remaining Ca2+ was still present in the external medium. 
Transients decreased with time and from 6 to 12 min, when Ca2+ was no longer present 
in the external medium no differences between knock-out and dysferlin-deficient fibers 
could be detected. This indicates that the increased Ca2+ transients are dependent on 
external Ca2+. 
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Figure 4.14.5 Increased Ca
2+












 transient amplitudes of dysferlin-deficient muscle fibers decrease with 
decreasing external Ca
2+
 concentration and adapt to wild-type Ca
2+
 transients when Ca
2+
 is 
depleted from the external medium. Data presented as mean +/- SEM. *P<0.05 vs. WT, N ≥ 3 
mice and 12 fibers per group. 
 
4.14.6 Post shock spark measurements reveal a significantly increased Ca2+ leak 
without increased spark frequency in dysferlin-deficient skeletal muscle fibers 
It was claimed that alterations of the T-tubule structure can have severe effects on Ca2+ 
homeostasis in skeletal muscle fibers due to increasing spark frequency (Wang et al., 
2005). As dysferlin-deficiency leads to T-tubule alterations, we examined Ca2+ sparks 
in dysferlin-deficient skeletal muscle fibers. Ca2+ sparks can not be detected in healthy 
murine skeletal muscle fibers. Therefore, Ca2+ sparks were measured after osmotic 
shock in dysferlin-deficient, wild-type and mdx (as disease control) skeletal muscle 
fibers. The results indicated that Ca2+ spark frequency was significantly increased in 
mdx fibers which lead to a significantly increased SR Ca2+ leak. These results were in 
line with previously published results (Wang et al., 2005). In contrast, dysferlin-deficient 
fibers did not show increased Ca2+ spark frequency related to wild-type fibers but 
nevertheless revealed an increased Ca2+ leak that was due to increased Ca2+ 
amplitude and increased Ca2+ spark duration. These results indicate that despite the 
altered T-tubule morphology in young dysferlin-defcient mouse muscle no increase in 
Ca2+ spark frequency was observed. Nevertheless, osmotic shock induced a 
significantly increased Ca2+ leak in dysferlin-defcient muscle fibers due to increased 
amplitude and duration of Ca2+ sparks.  





 spark frequency is not altered in dysferlin-deficient muscle fibers. Ca
2+
 
sparks were measured in wild-type, mdx and dysferlin-deficient muscle fibers after induction of 
osmotic shock. (a) Representative line scan images (∆F/F0, 0.96 ms/line) of WT, KO and mdx 
skeletal muscle fibers (b) Average spark frequency, normalized SR Ca
2+
 leak and 
spatiotemporal properties of Ca
2+
 sparks, such as amplitude, full duration at half maximum and 
spatial spread (full width at half maximum). Data presented as mean +/- SEM. *P<0.05 vs. WT, 
N = 4 mice and ≥ 112 fibers per group, horizontal scale bar: 200 ms, vertical scale bar: 10 µm. 
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4.15 Analysis of triad proteins in dysferlin-deficient mice 
It was demonstrated that dysferlin is located at the T-tubule system and is involved in 
biogenesis of this membrane system. Furthermore, it is known that the structure of the 
T-tubule system is significantly altered in dysferlin-deficient skeletal muscle fibers. 
These abnormalities of the T-tubule structure have influences on the process of EC-
coupling. All of these findings made it necessary to analyze the expression of T-tubule- 
and triad-associated proteins in dysferlin-deficient mouse muscle. Western blot 
analysis of dysferlin knock-out and wild-type muscle revealed no significantly altered 
expression levels in young dysferlin-deficient mice (9-11 weeks) as compared to wild-
type mice (figure 4.15). In aged dysferlin-deficient mice (50-66 weeks) expression of 
FKBP12 also known as calstabin 1 and junctophilin 1 was significantly decreased. 
Junctophilin connects the T-tubule system to the SR membrane and therefore is 
required for normal triad structure. Calstabin 1 is a protein binding to RyR and 
maintaining the closed state of the RyR after each contraction to prevent leakage of 
Ca2+ from the SR (Jayaraman et al., 1992, Brillantes et al., 1994). Furthermore, 
expression of Bin1, a protein involved in T-tubule biogenesis and T-tubule remodeling, 
was significantly increased in aged dysferlin-deficient mice, indicating an increased 
turnover of T-tubule membranes in aged dysferlin-deficient mice. 
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Figure 4.15 No alteration of triad- or T-tubule-associated proteins in dysferlin-deficient 
muscle. Western blot was carried out using quadriceps femoris muscle homogenates from 
young (9-11 weeks) and aged (50-66 weeks) wild-type and dysferlin-deficient mice, incubated 
with antibodies for triad or T-tubule proteins and detected by chemiluminescence. a) 
Representative original bots b) Average protein level of young (upper panel) and aged (lower 
panel) mouse muscle normalized to GAPDH. Wild-type protein levels were normalized to 1. 
Data presented as mean +/- SEM. *P<0.05 vs. WT, N = 3-6 mice per group. 
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4.16 Significantly increased fatigue resistance of dysferlin-deficient mice. 
More than 50 % of patients with dysferlin-deficient muscular dystrophy show above-
average motor performance prior to onset of muscle weakness. This is a feature not 
observed in any other form of muscular dystrophy. Most patients with other types of 
muscular dystrophy show decreased exercise capacity and the dystrophic muscle is 
characterized by decreased Ca2+ transients which is contrary to the increased Ca2+ 
release observed in dysferlin-deficient muscle fibers. Therefore, we measured exercise 
capacity of dysferlin-deficient mice at different stages of life. Ca2+ measurements of 
dysferlin-deficient skeletal muscle fibers revealed a significantly altered Ca2+ 
homeostasis with increased Ca2+ release. It is already known that dysferlin-deficient 
skeletal muscle fibers do not have significantly increased muscular strength (Chiu et 
al., 2009), therefore we had to address the question, whether these mice have 
increased endurance. At different time points between 4 and 90 weeks of age the 
running behavior of dysferlin-deficient and wild-type mice was recorded continuously. 
Over a period of three weeks the mean running velocity per day and the average 
running distance per day were recorded at each time point. As shown in figure 4.16b 
the mean weight of young and aged mice was not different. The results shown in 
figure 4.16.a revealed a significantly increased mean running velocity and running 
distance per day of young dysferlin-deficient mice related to wild-type mice. In contrast, 
old dysferlin-deficient mice showed significantly decreased running distances and a 
decreased mean running velocity most likely as a consequence of the dystrophic 
process. The running wheel experiment revealed a significantly increased resistance to 




Figure 4.16a: Young dysferlin-deficient mice show a significantly increased resistance to 
fatigue. At the age of 4, 12, 20, 40, 75 and 90 weeks the running wheel performance of wild-
type and dysferlin-deficient mice was tested over a period of three weeks. The mean running 
velocity per day (left) and the running distance per day (right) were recorded. Data presented as 
mean +/- SEM, *p>0.05, N ≥ 8 mice per group. 
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Figure 4.16b: No significant differences in body weight of young and aged dysferlin-
deficient mice. Average weight of 7-9 (left) and 77-81(right) weeks old wild-type and dysferlin-
deficient mice. Data presented as mean +/- SEM, N ≥ 17 mice per group.  
 
4.17 Increased fatigue resistance of knock-out mice is not due to a shift in fiber 
types. 
Generally, two main fiber types can be distinguished in the muscle, slow twitch type I 
fibers with low glycolytic high oxidative capacity, slow contraction time but high 
resistance to fatigue and fast twitch type II fibers which have high glycolytic but low 
oxidative capacity, fast contraction time but are also fast fatiguing. To examine whether 
the increased running distance and running velocity of young dysferlin-deficient mice is 
due to a shift in muscle fiber types, staining of succinate dehydrogenase (SDH) in 
isolated gastrocnemicus muscles was performed. SDH staining distinguishes between 
high and low oxidative muscle fibers as SDH is an enzyme located at mitochondria. As 
shown in figure 4.17, no differences in SDH positive, therefore type I fibers could be 
observed. Increased fatigue resistance of dysferlin-null mice is therefore not due to a 
shift in fiber type ratio. 
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Figure 4.17: No significant difference in muscle fibre type ratio of dysferlin-deficient and 
wild-type mouse muscles. Gastrocnemius muscles were isolated from 11 week old wild-type 
and dysferlin-null mice and SDH staining was carried out (succinate dehydrogenase; marker for 
fast muscle fibre type). a) Representative staining of wild-type and knock-out muscles. Scale 
bar: 50 μm. b) Average SDH positive type I fibres per mm
2
 and average fiber size in mm
2
, N = 3 
mice per group. 
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5. Discussion 
5.1 Dysferlin induces tubular membrane structures in non-muscle cells 
Mutations of dysferlin lead to muscular dystrophy but the pathomechanisms underlying 
the disease are so far unknown. The cell biological role of dysferlin was claimed to be 
membrane repair of skeletal muscle fibers as dysferlin-deficient fibers are not able to 
reseal their plasma membrane after injury. Nevertheless, this can not be the only 
physiological role of dysferlin, as dysferlin-deficient patients are initially without 
symptoms and even have a high level of fitness before onset of overt weakness that is 
not seen in any other form of muscular dystrophy. Membrane repair deficits should 
have influences on patients right after birth and therefore, this can not explain the 
pathology underlying the disease sufficiently and further physiological functions of 
dysferlin had to be analyzed.  
In previous experiments, it was detected that dysferlin induces tubular structures after 
heterologous expression in non-muscle cells. This was the first hint towards a new 
physiological function of dysferlin and lead to the hypothesis that dysferlin is involved in 
membrane tubulation and membrane organization. Therefore, these tubular structures 
needed to be further characterized. The dysferlin protein domain structure resembles 
that of its paralogues, myoferlin and otoferlin. All of them belong to the ferlin family, are 
type II membrane proteins and consist of several C2 domains. The structural similarity 
between the ferlin proteins suggests a similar protein function but expression in Cos 7 
cells indicated that only dysferlin was able to induce tubular structures. Myoferlin and 
otoferlin proteins localized at the ER as demonstrated by PDI costaining. This result 
indicates that among the ferlins dysferlin possibly is the only protein able to induce 
tubular structures after heterologous expression. This suggests a physiological role in 
membrane organization which is specific for dysferlin and probably will not be found for 
other ferlins. Previous experiments revealed that the tubules induced by dysferlin are 
membranous structures as they could be depleted by cholesterol extraction. This was 
further supported by the finding that the tubules do not colocalize with any cellular 
organelle. In contrast to that, the tubules seem to be in contact with the microtubule 
system as detected by disruption of the tubules by nocodazole. Phalloidin costaining 
indicated that the tubules are not in contact with the actin cytoskeleton which was 
confirmed by inhibition of the actin cytoskeleton by cyto D that did not disrupt the 
tubular structures but instead led to stabilization of the tubules. Van Deurs et al. 
demonstrated that treatment of cells with cyto D alone results in tubular invaginations 
from the plasma membrane. They claim that destruction of the actin cytoskeleton leads 
to destabilization of the plasma membrane and therefore tubular invaginations 
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mediated by microtubules (Van Deurs et al., 1996). The dysferlin induced tubules are 
continuous with the plasma membrane as shown by FM4-64 costaining. Cyto D 
treatment therefore probably increases tubulation induced by dysferlin by destructing 
the actin cytoskeleton and promoting the interaction with the microtubule system 
resulting in sustained invagination of the plasma membrane. The effect of cyto D can 
probably be further explained by the fact that the tubules are not static but are, like all 
membrane systems, dynamic structures. Only recently this was shown by our group by 
live microscopy experiments with dysferlin-transfected cells (Drzymalski, not 
published). Cyto D not only leads to inhibition of the actin cytoskeleton but further 
results in a cell cycle arrest which possibly leads to inhibition of tubule movement and 
thereby stabilization and pronounced appearance of these structures. 
Dysferlin is a large protein of about 230 kDa containing several protein domains. To 
determine which domains are essential for tubulation and to analyze the minimal 
required number of C2 domains, several truncated dysferlin constructs were cloned, 
expressed in Cos 7 cells and analyzed for tubule induction. Two constructs containing 
only the last two C2 domains with or without the transmembrane (TM) domain (see 
figure 4.3.2) were analyzed. These were not able to induce tubular structures. A 
minidysferlin found in a patient with a moderate late onset dysferlinopathy that contains 
the last two C2 domains with the TM domain and an N-terminal part resulting from a 
frame shift mutation was suggested to be a good candidate for gene transfer studies. In 
our experiments this minidysferlin did not induce membrane tubulation which indicates 
that it does not contain all functionally relevant properties of the full-length dysferlin. 
Minidysferlin 3 containing the last two C2 domains, the TM domain and additionally the 
C2A domain was demonstrated to efficiently mediate membrane repair like the full-
length protein (Azakir et al. 2012). Also this truncated version of dysferlin was not able 
to induce membrane tubulation after heterologous expression. None of the tested 
truncated dysferlin constructs did induce membrane tubules. This indicates that all C2 
domains are necessary for proper function of dysferlin. Also the TM mutant of dysferlin 
did not induce membrane tubulation suggesting that also the TM domain is required for 
proper dysferlin function. In addition to the truncated dysferlin proteins pathogenic 
mutants were tested for membrane tubulation. Five different mutants were tested, four 
of them harboring point mutations in one of the C2 domains (C2A, C2C, C2D or C2E) 
and one containing a point mutation in between two C2 domains (see figure 4.3.2). 
Again, none of these mutated dysferlin constructs induced membrane tubulation. 
Interestingly, the mutant containing the mutation in between the C2 domains did show 
membrane tubulation, although in a lesser proportion of cells compared to the full-
length dysferlin which further supports a crucial role of the C2 domains in tubule 
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formation. It is known that dysferlin localizes to the developing T-tubule system in 
C2C12 cells, a murine myoblast cell line. All of the constructs mentioned above were 
additionally expressed in these cells to analyze their subcellular localization. In line with 
the results obtained from the Cos 7 experiments, none of the truncated dysferlin 
constructs and pathogenic dysferlin mutants did show a tubular expression pattern like 
the full-length dysferlin. This suggests no localization of these constructs at the tubular 
structures previously identified as T-tubule membranes in C2C12 cells (Klinge et al., 
2007). Interestingly, only the dysferlin mutant containing the mutation not in the C2 
domains did show a partial tubular expression pattern indicating partial T-tubule 
localization. These results further indicate that the full-length protein is required for 
protein function and emphasize the crucial role of the dysferlin C2 domains.  
Further investigation of the dysferlin-induced tubules revealed that these structures 
contain high amounts of the phospholipids PIP2 and PIP3 an important component of 
T-tubular membranes. Furthermore, dysferlin is recruited to PIP2-containing vesicles 
that are induced by expression of PIP2 kinase. In contrast, truncated dysferlin 
constructs and pathogenic mutants were not recruited to these structures. When 
dysferlin was expressed together with the PIP2 phosphatase synaptojanin 1, which 
dephosphorylates PIP2, dysferlin did not induce membrane tubulation most likely due 
to PIP2 depletion. These results support that dysferlin-induced tubules are 
membranous structures containing high amounts of the phospholipids PIP2 and PIP3 
and further suggest that dysferlin is able to bind to phospholipids, especially PIP2. As 
these lipids that are found in T-tubule membranes are present in dysferlin-induced 
tubules these structures show biochemical similarities with the T-tubule system of 
skeletal muscle.  
The T-tubule system is a highly organized membrane system that invaginates from the 
plasma membrane into the muscle fiber. Therefore it was further investigated whether 
dysferlin-induced tubules also invaginate from the plasma membrane. Staining of the 
tubules with the membrane dye FM4-64 indicated that the tubules are continuous with 
the plasma membrane as after 1 min of staining, the dye will not be endocytosed and 
can only reach the tubules by lateral diffusion through the plasma membrane. This 
indicates that these tubules are continuous with the plasma membrane suggesting 
dysferlin-mediated plasma membrane invagination, a morphological similarity to 
skeletal muscle T-tubule system. 
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5.2 Dysferlin binds to phopholipids and induces membrane curvature in vitro 
Coexpression of dysferlin with the PIP2 kinase revealed that dysferlin is recruited to 
PIP2-containing vesicles. This indicates ability of dysferlin to bind to phospholipids, 
especially PIP2. The dysferlin C2A domain binds to PIP2 in a Ca2+-dependent manner 
and all other C2 domains are able to bind negatively charges phospholipids although 
with weaker binding affinity compared to the C2A domain (Therrien et al., 2009). This, 
however, was not analyzed for the full-length dysferlin protein. Our PIP-strip 
experiments indicated binding of the full-length dysferlin protein to PIP2 which was 
further supported by the results of the flotation assay. This shows that not only the C2A 
domain, but also the dysferlin full-length protein is able to bind phospholipids, 
especially PIP2 in presence of Ca2+. Binding of dysferlin to PIP2 was abolished by a 
pathogenic mutation of the dysferlin C2A domain which highlights the crucial role of this 
domain in dysferlin function. This specific function was further substantiated by a 
liposome binding experiment which was carried out with single C2 domains of dysferlin. 
Only the C2A domain of dysferlin was able to induce aggregation of liposomes in 
presence of Ca2+. The C2 domains were expressed as GST-tagged proteins. GST is 
known to cluster with other GST molecules. The liposome aggregation potential of the 
C2A domain was therefore possibly mediated by clustering of GST and thereby 
clustering of liposomes that were bound to the C2A domain. As this effect was not 
observed with the other C2 domains, these domains seem to play only a minor role in 
lipid binding but nevertheless are crucial for dysferlin function. Minidysferlin 3 was able 
to bind PIP2 probably due to the presence of a functional C2A domain in this protein. 
Dysferlin is localized at the T-tubule system, is involved in its biogenesis and is able to 
induce T-tubule like structures in non-muscle cells containing phospholipids that are 
normally present in T-tubule membranes. These findings indicate that dysferlin plays a 
role in organization of biological membranes which was further supported by the fact 
that dysferlin is able to bind to phospholipids in vitro. Unpublished experiments 
demonstrated that dysferlin-induced tubules in Cos 7 cells colocalize with Bin1-induced 
tubules. As Bin1 is already known to mediate membrane tubulation, this observation 
further supported the hypothesis that dysferlin is also involved in membrane 
organization. Liposome tubulation experiments were carried out to investigate the 
membrane tubulation properties of dysferlin. Indeed, dysferlin was able to induce 
tubulation of liposomes from Folch fraction lipids in vitro which was further enhanced by 
addition of PIP2. The C2A mutant of dysferlin and minidysferlin 3 were not able to 
induce membrane tubulation which indicates that full-length dysferlin is required for 
correct function in vitro. Minidysferlin 3 seems to be able to bind to PIP2 but is not able 
to induce membrane tubulation. The C2A mutant additionally was not able to tubulate 
Discussion  90 
   
membranes like the full-length protein which again highlights the crucial role of the C2A 
domain in proper dysferlin function. These results are consistent with the findings from 
the Cos 7 experiments where it was shown that the full-length dysferlin protein is 
needed for its correct function.  
As dysferlin is involved in T-tubule biogenesis the membrane tubulating function of 
dysferlin that we observed in in vitro experiments leads to the suggestion that dysferlin 
plays a role in formation of the T-tubule system during its development. This would also 
explain the abnormal conformation of the T-tubule system that was detected in 
dysferlin-deficient murine muscle. This hypothesis is also consistent with results from 
studies using an in vivo model of muscle regeneration. Mouse muscle was treated with 
notexin to break down the muscle fiber and to induce regeneration. In normal muscle 
the T-tubule system regenerates normally after notexin treatment but in dysferlin-
deficient mouse muscle the T-tubule system did not regenerate properly but revealed 
an abnormal configured structure (Klinge, not published). These findings provide 
evidence that the membrane tubulation capacity obtained in vitro is also relevant in 
vivo. 
The abnormal T-tubule system due to dysferlin-deficiency further explains the defective 
membrane repair mechanism and defective regeneration process detected in dysferlin-
deficient mouse muscle. The T-tubule system provides a membrane reservoir for the 
plasma membrane in muscle fiber regeneration and is involved in transport of 
membranes (Engel and Franzini-Armstrong, 2004). Furthermore, it was shown that 
dysferlin translocates from the T-tubule system towards the membrane lesions (Klinge 
et al., 2007). This indicates that the T-tubule system also provides proteins and 
possibly membranes needed for the muscle membrane repair mechanism. This 
suggests that abnormal T-tubule development due to absence of dysferlin leads to 
deficits in muscle fiber regeneration and repair. 
McMahon et al. suggested that C2 domains mediate membrane curvature by inserting 
their amphiphatic helices into one monolayer of a biological membrane to the level of 
the glycerol backbones of the lipids (McMahon et al., 2010). This is enough to induce 
local curvature of both lipid bilayers. Further they hypothesize that large scale 
deformation of membranes, like tubulation of liposomes can only be mediated by high 
density of C2 domains as the curvature effects of these domains are additive. This can 
be achieved by several single C2 domains but would be much more effective when the 
C2 domains are coupled in a dimer. This suggests that all of the seven C2 domains 
present in the dysferlin protein mediate local curvature of the T-tubule membrane, but 
the additive effect of the multi C2 domains is needed for induction of membrane 
tubulation, which is consistent with our observations in the tubulation experiments. 
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The Cos 7 experiments indicate that the TM mutant of dysferlin was not able to induce 
tubular structures and we hypothesize that this observation is due to incorrect 
localization of the protein. Therefore, we suggest that the TM domain of the dysferlin 
protein is needed for proper membrane localization of dysferlin but is probably not 
involved in membrane deformation. This is further highlighted by the fact that the 
dysferlin protein structure is reminiscent of the structure of a tail-anchored protein. Tail-
anchored proteins consist of a single TM domain which is close to the C-terminus and 
anchors the protein in the membrane the entire N-terminal portion of the protein facing 
the cytosol. The TM domain of tail-anchored proteins is crucial for proper localization of 
the whole protein as it contains a signal sequence for its posttranslational membrane 
insertion. So far it was not determined whether dysferlin belongs to the group of tail-
anchored proteins but its protein structure is suggesting this.  
5.3 Dysferlin-deficiency influences Ca2+ homeostasis 
Dysferlin-deficient murine muscle is characterized by an abnormal morphology of the 
T-tubule system. The T-tubule system is necessary for propagation of the action 
potential into the interior of the muscle fiber thereby initiating the mechanism of 
excitation-contraction coupling (EC-coupling) and allowing highly synchronized 
contraction of the whole muscle fiber at the same time. Therefore we investigated 
probable functional influences of the altered T-tubule morphology on EC-coupling by 
Ca2+ measurements. Interestingly, Ca2+ release was significantly increased in young 
dysferlin-deficient muscle fibers related to wild-type fibers. The relaxation time as a 
measure for SR Ca2+-ATPase (SERCA) activity and the time to peak as a measure of 
the contractility of the cell were not altered and the resting Ca2+ concentration was also 
not different in knock-out compared to wild-type fibers. These results indicate that Ca2+ 
homeostasis is significantly altered in dysferlin-deficient skeletal muscle leading to 
increased Ca2+ release. As mentioned above, muscular dystrophy can have severe 
influences on Ca2+ homeostasis and leads to reduction of Ca2+ release for example in 
mdx mouse muscle. Therefore, Ca2+ measurements were additionally carried out in 
mdx muscle fibers and results were compared to wild-type and dysferlin knock-out 
fibers. As published previously, Ca2+ release was significantly decreased in mdx 
muscle fibers and SERCA function was significantly decreased related to wild-type 
fibers. Resting Ca2+ concentration was not altered in mdx fibers. Contrary to that, many 
studies on Ca2+ homeostasis in mdx muscle demonstrate that the resting Ca2+ 
concentration is significantly increased in these muscles but still other studies exist, 
that do not find an altered resting Ca2+ concentration (Pressmar et al., 1994). 
Nevertheless, the results indicate an altered Ca2+ homeostasis in mdx mice that is 
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consistent with previous published results. These results are completely contrary to the 
alterations found in dysferlin-deficient skeletal muscle. Therefore, alteration in Ca2+ 
homeostasis with increased Ca2+ release in young dysferlin-deficient skeletal muscle is 
due to the absence of the dysferlin protein and not due to the process of muscular 
dystrophy.  
The increased Ca2+ release would suggest an increased SR Ca2+ content, as this is the 
main contributor to Ca2+ release in skeletal muscle fibers. Caffeine experiments 
demonstrated that the SR Ca2+ content was not significantly altered in dysferlin knock-
out muscle fibers. This finding is in line with the normal SERCA function but does not 
explain the increased Ca2+ release. Two further Ca2+ entry mechanisms are known so 
far in skeletal muscle. Store-operated Ca2+ entry (SOCE) is a mechanism that comes 
into action when the Ca2+ content of the SR decreases and is necessary to counteract 
appearance of fatigue. Excitation-coupled Ca2+ entry (ECCE) is a mechanism of Ca2+ 
entry independent of SR Ca2+ content but dependent on stimulation of the muscle fiber 
and interaction of DHPR and RyR. The Ca2+ depletion experiment indicates, that Ca2+ 
transient amplitudes of knock-out muscle fibers decrease with time when the Ca2+ 
concentration in the surrounding medium decreases but are still significantly increased 
compared to wild-type fibers. Only when Ca2+ is completely absent from the 
surrounding medium no difference in Ca2+ transient amplitudes can be observed any 
more. This indicates that the increased Ca2+ release is dependent on external Ca2+, 
probably through the mechanism of ECCE. The transients of the knock-out fibers 
decrease during the first minutes after changing to Ca2+-free perfusion when the Ca2+ 
content in the external medium decreases and SOCE does not play a role yet as the 
SR still contains normal levels of Ca2+. These experiments point out that increased 
Ca2+ release in dysferlin-deficient skeletal muscle fibers is due to increased Ca2+ entry 
into the muscle fiber, probably by the mechanism of ECCE, but not SOCE. Only 
recently it was confirmed in our lab that SOCE is not increased in dysferlin-deficient 
skeletal muscle fibers. Re-addition of Ca2+ into the external medium after store 
depletion did not lead to increased Ca2+ entry in dysferlin-null muscle fibers related to 
wild-type fibers (Büssenschütt, not published). So far it is known that the mechanism of 
ECCE involves coupling of DHPR and RyR and Bannister et al., claimed that Ca2+ 
enters the muscle fiber through the DHPR itself. In further experiments Ca2+ entry 
through the DHPR has to be analyzed to prove our hypothesis that increased ECCE 
accounts for the increased Ca2+ release.  
Wang et. al. suggested that subtle membrane alterations induce Ca2+ sparks due to 
uncoupling of DHPR and RyR. The DHPR is not only needed to activate Ca2+ release 
from the RyR, but also mediates inactivation of the same channel. Altered coupling of 
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the SR and T-tubule membranes due to osmotic stress or fatigue exercise prevents the 
inhibitory function of DHPR on the RyR channel so that Ca2+ sparks occur. Membrane 
fragility for example due to dystrophin-deficiency further increases osmotic shock or 
exercise-induced frequency of Ca2+ sparks as the membrane is more susceptible to 
stress. Our experiments reveal no increased Ca2+ spark frequency in dysferlin-deficient 
muscle fibers after induction of osmotic shock. In contrast to that, Ca2+ spark frequency 
was significantly increased in mdx fibers which is consistent with previously published 
results. This again indicates a different pathophysiology underlying dysferlin-deficiency 
as compared to dystrophin-deficiency. Further this suggests that coupling of DHPR and 
RyR is not altered in young dysferlin-deficient mice. This was additionally supported by 
the observation that fatigue exercise did not significantly change Ca2+ release in 
dysferlin-null muscle fibers. It was demonstrated that eccentric exercise induces 
morphological changes of the T-tubule system (Takekura et al., 2001b, Wang et. al., 
2005) which leads to increased Ca2+ leak from the SR and therefore changes in EC-
coupling (Wang et al., 2005, Bellinger et al., 2008). Our data indicate an increased 
resting Ca2+ level in both wild-type and knock-out mice after stress exercise. This is 
probably due to an increased Ca2+ leak from the SR induced by morphological changes 
of the T-tubule membrane, however, no significant influences on Ca2+ release could be 
observed in dysferlin knock-out or wild-type mouse muscle fibers. In mdx mice it was 
demonstrated that exercise stress leads to uncoupling of DHPR and RyR which results 
in induction of muscular dystrophy (Wang et al., 2005). As Ca2+ release is not 
significantly influenced in dysferlin knock-out muscle fibers by stress exercise, this 
suggests again that coupling of DHPR and RyR is not altered.  
In conclusion, Ca2+ imaging in young dysferlin-deficient mouse muscle fibers revealed 
a significantly altered Ca2+ homeostasis with increased Ca2+ release. Despite the fact 
that the T-tubule system is abnormally configured in dysferlin-deficincy this has 
probably no influence on coupling of DHPR and RyR. This suggests that the altered 
Ca2+ homeostasis in young dysferlin-deficient mice does not lead to induction of muscle 
degeneration but on the contrary may explain increased exercise capacity patients 
before onset of symptoms. 
Ca2+ measurements in dysferlin-deficient skeletal muscle fibers from aged mice 
revealed increased Ca2+ transient amplitudes like in the young mice, but the difference 
was not statistically significant at single frequencies. Furthermore, decreased SERCA 
activity and decreased contractility were observed in the muscle fibers from old 
dysferlin knock-out mice. This indicates that dysferlin-deficiency also leads to an 
altered Ca2+ homeostasis in muscle fibers of aged mice with differences related to 
fibers from young dysferlin knock-out mice. These differences possibly are due to 
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secondary alterations and not primary effects underlying the dysferlin deficiency. One 
possible explanation is that ECCE is still increased in aged dysferlin-deficient mice but 
SR Ca2+ content is decreased due to the decreased SERCA-function. 
5.3.1 Alteration in Ca2+ homeostasis is specifically due to dysferlin-deficiency 
Dysferlin-deficiency leads to an abnormal morphology of the T-tubule system and to an 
alteration in Ca2+ homeostasis which shows different characteristics in young compared 
to aged mice. These alterations could be a direct effect mediated by the absence of the 
dysferlin protein itself or could be indirect effects due to secondary alterations of triad 
or T-tubule-associated proteins. Western blots of mouse muscle homogenates from 
dysferlin-deficient mice did not reveal alterations in expression of any T-tubule or triad-
associated protein that was tested. This suggests that alterations in T-tubule system 
and Ca2+ homeostasis are direct effects due to the deficiency of the dysferlin protein. In 
contrast to that, muscle homogenates from aged mice indicated significant lower 
amounts of calstabin 1 and junctophilin 1 protein expression in knock-out related to 
wild-type mice. Junctophilin stabilizes the connection of the T-tubule system with the 
SR membrane. The protein is therefore necessary for maintenance of the triad 
structure and absence of this protein leads to a disrupted triad and T-tubule structure. 
In dysferlin-deficient skeletal muscle where the T-tubule system is already altered this 
probably leads to secondary alterations of T-tubule or triad proteins. The altered T-
tubule structure may lead to loss of proper localization of junctophilin 1 and therefore 
depletion of the protein. This observation may explain differences in Ca2+ release that 
had been detected in muscle fibers from aged dysferlin-deficient mice compared to 
young mice. The decreased contractility observed in these muscle fibers could be due 
to an additional defect mediated by the absence of the junctophilin 1 protein. 
Calstabin 1 was also found to be less expressed in aged dysferlin-deficient muscle. 
The protein stabilizes RyR1 in its closed state therefore, absence of calstabin 1 leads 
to increased open probability of the receptor which might result in a Ca2+ leak from the 
SR due to increased frequency of Ca2+ sparks. In addition to the decreased SERCA 
function this would result in decreased SR Ca2+ content which has to be analyzed in 
further experiments. Interestingly, SERCA protein was not observed to be less 
expressed in aged dysferlin-deficient muscle indicating that the decreased SERCA 
function has to be explained by decreased activity and not decreased expression. 
Bin1 protein was observed to be expressed at higher levels in muscle from aged 
knock-out compared to wild-type mice. The protein is known to play a role in 
regeneration of the T-tubule system. Loss of Bin1 as well as dysferlin lead to an 
abnormal T-tubule structure, but the T-tubule system in both cases is still present. This 
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indicates that both proteins are not alone involved in development and maintenance of 
T-tubule structure and probably take over each other’s function in absence of one of 
the proteins. Therefore Bin1 expression is increased in aged dysferlin-deficient mouse 
muscle witch further indicates an increased membrane turnover. This highlights further 
that in aged dysferlin-deficient muscle alteration of the T-tubule structure seems to be 
present at higher degrees as compared to young muscle, where Bin1 expression is not 
increased. 
In conclusion, the abnormal T-tubule system in dysferlin-deficient mice is a 
consequence of the loss of the dysferlin protein. In aged muscle this defect is further 
impaired by secondary alterations probably as a consequence of the dystrophic 
process. In aged dysferlin-deficient muscle, secondary alterations of junctophilin 1 and 
calstabin 1 expression may account for differences in Ca2+ release compared to young 
dysferlin-deficient mouse muscle. 
5.4 Dysferlin-deficiency leads to increased resistance to fatigue 
Increased Ca2+ release was observed in dysferlin-deficient skeletal muscle fibers from 
young mice. The question remains now, whether this alteration in Ca2+ homeostasis 
influences muscle physiology and exercise properties of dysferlin-deficient mice. It was 
already demonstrated that dysferlin-deficient mice do not reveal increased muscle 
strength (Chiu et al., 2009). A running wheel experiment to test longitudinally the motor 
performance of wild-type and dysferlin knock-out mice was carried out and dysferlin-
deficient mice indeed run significantly longer distances per day and showed 
significantly higher running velocity compared to wild-type mice of the same age. Two 
main muscle fiber types exist in skeletal muscle. Type I fibers are specialized in long 
duration contractile activities and type II fibers are specialized in short duration 
anaerobic activities and are fast fatiguing. Interestingly, type I fibers are found to a 
higher extent in endurance athletes and type II fibers in power athletes and it was 
proposed that endurance training may lead to a shift in fiber types which increases 
motor performance. The increased running behavior of the young dysferlin-deficient 
mice could therefore be due to an increased level of type I fibers. However, this was 
not the fact as the ratio of type I to type II fibers was not different in young dysferlin 
knock-out mice compared to wild-type mice. Furthermore, no difference in weight of 
wild-type and knock-out mice was observed that could have influenced motor 
performance. The results from the running wheel experiment indicate therefore that 
young dysferlin-deficient mice have a significantly increased resistance to fatigue which 
is probably due to the altered Ca2+ homeostasis and the increased ECCE mechanism 
observed in muscle fibers of these mice. Motor performance of dysferlin-deficient mice 
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declines with age so that with the age of 20 weeks no differences between dysferlin-
deficient and wild-type mice were observed any more. This is probably due to 
secondary alterations due to onset of muscular dystrophy. Due to ongoing and 
increasing muscular dystrophy, dysferlin-deficient mice at the age of 70 weeks show 
significantly decreased motor performance related to wild-type mice. Interestingly, this 
time course of running behavior can be compared to motor performance of 
dysferlinopathy patients which have a high level of fitness in childhood, before onset of 
muscular dystrophy symptoms and only reveal decline of motor performance in the 2nd 
decade of life, after onset of symptoms. These results highly indicate that absence of 
dysferlin leads to changes in Ca2+ homeostasis which increases motor performance in 
mice and human and only in older age secondary mechanisms lead to damage of 
muscle fibers and therefore to muscular dystrophy. 
5.5 Dysferlin localizes to the T-tubule system in cardiomyocytes 
Besides its expression in skeletal muscle, dysferlin is expressed even in higher 
amounts in heart muscle but the role of dysferlin in the heart was not studied 
intensively so far. By colocaization of dysferlin with DHPR we demonstrated for the first 
time that also in heart muscle dysferlin is localized at the T-tubule system. Dysferlin is 
involved in T-tubule biogenesis in skeletal muscle by mediating tubulation of the T-
tubule membrane system. This suggests that dysferlin-deficiency possibly influences 
the T-tubule structure in cardiomyocytes like it was observed in skeletal muscle. The 
presence of cardiomyopathies in some patients and in animal models further highlights 
that dysferlin plays an important role in heart muscle. Staining of the T-tubule system 
with the membrane dye and T-tubule marker di8ANEPPS indicated that the T-tubule 
system in dysferlin-deficient heart muscle is irregularly configured and more 
longitudinally oriented compared to wild-type mice which proved that dysferlin is 
necessary for proper T-tubule structures in heart as well as in skeletal muscle. 
Interestingly, the observed phenotype resembles the phenotype of cardiomyocytes 
after induction of myocardial infarction (MI) which shows dilated and longitudinal 
oriented T-tubules that are undergoing a process of T-tubule regeneration (Wagner et 
al., 2012). Furthermore, Bin1, a protein that is like dysferlin involved in membrane 
tubulation and T-tubule development in skeletal muscle was recently implicated in the 
process of T-tubule remodeling in the heart (Lyon et al., 2012). Therefore, we analyzed 
dysferlin expression in heart muscle from rats after induction of MI and compared it to 
sham-treated rat muscle. Dysferlin expression was significantly upregulated in heart 
muscle after MI which indicated a possible role of dysferlin in the process of T-tubule 
remodeling after MI. This further suggests that dysferlin is not only involved in T-tubule 
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development and maintenance of proper T-tubule structure in skeletal but also in heart 
muscle and that dysferlin-deficiency not only leads to defects in skeletal but also in 
heart muscle. Therefore dysferlin-deficiency may have additional influences on cardiac 
health.  
5.6 Dysferlin-deficiency influences Ca2+ homeostasis in cardiomyocytes 
Analysis of dysferlin in heart muscle revealed that the protein is located at the T-tubule 
system and is involved in maintenance and probably development of normal T-tubular 
structures in cardiomyocytes. Like in skeletal muscle this may have influences on the 
process of EC-coupling and therefore Ca2+ homeostasis of the heart. Ca2+ imaging in 
cardiomyocytes indicated that dysferlin-deficiency leads to significantly decreased SR 
Ca2+ stores. Under normal physiological conditions this deficit can be adjusted by other 
mechanisms so that no differences in Ca2+ release can be observed between wild-type 
and knock-out cardiomyocytes. SERCA function and contractility of the cells are also 
not influenced by dysferlin-deficiency under normal conditions. The decreased SR Ca2+ 
content is probably balanced by Ca2+ entry through the DHPR in dysferlin-deficient 
cardiomyocytes. This would result in additionally increased Na+/Ca2+-exchanger (NCX) 
function as the increased amount of Ca2+ entering the cell has to be exported again out 
of the cell by the NCX. NCX function can be measured by the decline of the caffeine-
induced Ca2+ transient which is indeed faster by trend in dysferlin-deficient 
cardiomyocytes. These results are in line with biometric data of the mice which showed 
no signs of hypertrophy as they had a normal heart/body weight ratio. When stress was 
induced in dysferlin-null cardiomyocytes, here done by isoprenaline treatment, Ca2+ 
release was observed to be significantly decreased compared to wild-type cells. This 
indicates that in stress situations the decreased Ca2+ content of the SR can no longer 
be balanced and deficits of the dysferlin-deficient cardiomyocytes are unmasked. 
Therefore, dysferlin-deficiency probably has no effect on cardiomyocytes under normal 
physiologic conditions but may have severe influences on the heart in stress situations. 
Ca2+ release in dysferlin-deficient cardiomyocytes was significantly decreased after an 
unstimulated period of 30 s during isoprenaline treatment. This indicates that the cells 
loose Ca2+ from the SR during diastole, which would explain the decreased Ca2+ 
content in these cells. This was further analyzed by spark measurements that 
demonstrated a significantly increased Ca2+ spark frequency and therefore a 
significantly increased SR Ca2+ leak in dysferlin-deficient cardiomyocytes which was 
further increased by isoprenaline-induced stress. The appearance of Ca2+ sparks 
during diastole of the heart is to a certain level normal but if the spark frequency 
increases, this may have severe influences on heart physiology as an increased Ca2+ 
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leak may trigger arrhythmia and therefore heart failure. Increased Ca2+ leak from the 
SR during diastole leads to increased Ca2+ export by the NCX and therefore import of 
Na+ into the cell which may result in membrane depolarization and arrhythmogenic 
events during diastole. The presence of an increased SR Ca2+ leak in dysferlin-
deficient cardiomyocytes was further supported by the observation of a significantly 
increased number of proarrhythmogenic events during detection of Ca2+ transients. 
These nonstimulated events occurred during steady-state stimulation as well as in 
situations when stimulation was paused and their number was significantly increased 
when cells were treated with isoprenaline. These results clearly point out that dysferlin-
deficiency has severe effects on cardiomyocyte function which can be compensated 
under normal physiological situations but may lead to heart failure in stress situations. 
In heart failure, T-tubule remodeling is observed which leads to unorganized T-tubule 
structures and repositioning of the DHPRs away from the Z-line resulting in some 
orphaned RyRs (Song et. al., 2006). It was claimed that these orphaned RyRs are 
physically separated from the DHPRs and therefore do not respond to normal 
physiological stimulation. However, these receptors can be activated later with variable 
latencies through nearby Ca2+ elevations. These are due to RyRs that are normally 
triggered to release Ca2+. This delayed reaction results in Ca2+ sparks that occur during 
diastole of the heart. The abnormal T-tubule structure in dysferlin-deficient 
cardiomyocytes may lead to some orphaned RyRs that increase Ca2+ spark frequency 
under normal physiological conditions. Under basal conditions this increase is probably 
not high enough to trigger severe arrhythmias and the resulting decreased Ca2+ content 
is probably balanced by increased Ca2+ entry through the DHPR so that the dysferlin-
deficiency does not have severe influences on the heart under normal physiological 
conditions. These observations are reminiscent of a disease called catecholaminergic 
polymorphic ventricular tachycardia (CPVT), an arrhythmogenic disorder of the heart. 
No structural heart disease or electrocardiogram abnormalities are present in these 
patients but emotional or physical stress may lead to severe arrhythmias and sudden 
cardiac death (Wehrens et al., 2003). CPVT patients reveal mutations of the RyR2 that 
are leading to decreased binding affinity of calstabin 2 to the receptor despite the fact 
that under basal conditions calstabin 2 is able to bind to RyR2 normally. Physical or 
emotional stress leads to activation of the sympathetic nervous system and release of 
catecholamines and hence activation of ß-adrenal receptors. This induces RyR2 
phsophorylation by protein kinase A and thereby dissociation of calstabin 2 from RyR2 
leading to increased open probability of the receptor (Marx et al., 2002). This is part of 
the normal fight or flight response but in these patients decreased binding affinity of 
calstabin 2 to RyR2 leads to a severe RyR2 leak in stress situations which results in 
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arrhythmias and sudden cardiac death. As compared to the CPVT patients dysferlin-
deficiency leads to an increased Ca2+ leak that is also present in basal conditions, but 
which can be balanced under normal conditions. In stress situations the effect of 
catecholamines possibly is added to the basal Ca2+ leak and Ca2+ sparks are further 
increased due to calstabin dissociation form the RyR. This results in fatal membrane 
depolarization during diastole and therefore occurrence of arrhythmias.  
In conclusion, the disorganized T-tubule structure in cardiomyocytes due to dysferlin-
deficiency probably leads to basal alterations in Ca2+ homeostasis which can be 
compensated under normal physiological conditions but in combination with emotional 
or physical stress this has severe influences on heart physiology. In stress situations, 
dysferlin-deficiency in heart may induce fatal arrhythmias which may also result in 
sudden cardiac death. This observation is of high clinical relevance to patients affected 
by dysferlin-deficiency. Therefore, alteration of Ca2+ homeostasis in dysferlin-deficient 
muscular dystrophy should be further investigated as a possible translational 
therapeutic approach. 
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6. Conclusion 
Dysferlin is localized to the T-tubule system of the skeletal muscle and is involved in 
the biogenesis of this membrane system. The dysferlin protein structure and its 
homology to Fer1 suggested a function of the protein in membrane binding. Preliminary 
results revealed a membrane tubulating function of dysferlin after heterologous 
expression in non-muscle cells. We were now able to reveal that these structures are 
membranes containing biochemical and morphological properties of the T-tubule 
system in skeletal muscle with high amounts of PIP2 and continuity with the plasma 
membrane. Further we were able to show for the first time that the full-length dysferlin 
is able to bind to PIP2 and to mediate membrane tubulation in vitro. These 
observations suggest that dysferlin is involved in tubulation of the T-tubule system 
during its development, which explains the unorganized T-tubule system in dysferlin-
deficient muscle. This tubulating function of dysferlin is specific for the protein among 
the ferlins and for the full-length protein. The minidysferlins tested in this study were not 
able to functionally replace the full-length protein. The abnormal T-tubule development 
due to dysferlin-deficiency explains the defective membrane repair mechanism and the 
defective regeneration process detected in dysferlin-deficient mouse muscle. The 
abnormal T-tubule system further leads to an altered Ca2+ homeostasis in young 
dysferlin-deficient mice which results in increased resistance to fatigue. This alteration 
was found to be a direct effect of dysferlin-deficiency and was not due to secondary 
alterations of triad or T-tubule proteins. This additionally explains the increased 
exercise capacity in dysferlinopathy patients which can be observed before onset of 
symptoms. When dysferlin-deficient mice age, secondary alterations due to the onset 
and increase of muscular dystrophy lead to further structural alterations of the T-tubule 
system and therefore deficiencies in Ca2+ homeostasis that are not observed in young 
mice.  
Further we analyzed the role of dysferlin in the heart. As in skeletal muscle dysferlin 
was detected at the T-tubule system in heart muscle and dysferlin-deficiency resulted 
in abnormal configuration of the T-tubule system in cardiomyocytes. We were able to 
detect an increase of the dysferlin protein after MI indicating a role of the protein in T-
tubule remodeling. Further the aberrant T-tubule system in dysferlin-deficiency leads to 
a defective Ca2+ homeostasis which can be compensated under normal physiological 
conditions but which may lead to severe arrhythmias in stress situations. This indicates 
that dysferlin-deficiency does not only lead to alterations in skeletal muscle of patients 
but additionally may have severe influences on heart physiology which is of high 
clinical relevance for patients affected by dysferlin deficiency. 
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